



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: XXXX XXX/XXXXX	A2	(11) International Publication Number: WO 00/04196
		(43) International Publication Date: 27 January 2000 (27.01.2000)

(21) International Application Number: PCT/US99/15860

(22) International Filing Date: 13 July 1999 (13.07.1999)

(30) Priority Data:

09/165,794 02 October 1998 (02.10.1998) US
60/092,697 14 July 1998 (14.07.1998) US

(60) Parent Application or Grant

CISTEM MOLECULAR CORPORATION [/];
(). KAUFFMAN, Stuart, A. [/]; (). BALLIVET, Marc [/];
(). KAUFFMAN, Stuart, A. [/]; (). BALLIVET, Marc [/];
(). GAY, David, A. ; ().

Published

(54) Title: CIS ACTING NUCLEIC ACID ELEMENTS AND METHODS OF USE

(54) Titre: ELEMENTS D'ACIDES NUCLEIQUES A ACTIVITE CIS ET METHODES D'UTILISATION

(57) Abstract

The invention provides a method of identifying nucleic acid molecules that contain cis acting nucleic acid elements. Also provided is a method of isolating nucleic acid binding factors. The invention also provides methods of identifying compounds that are cis acting nucleic acid element analogs, compounds that are nucleic acid binding factor analogs, compounds that selectively bind cis acting nucleic acid elements and compounds that selectively displace binding between a nucleic acid binding factor and a cis acting nucleic acid element or between nucleic acid binding factors. Also provided is a method of determining a binding state of a nucleic acid. Pluralities of isolated nucleic acid molecules containing cis acting nucleic acid elements, of isolated cis acting nucleic acid elements and of isolated nucleic acid binding factors are also provided. The invention further provides methods of treating pathological conditions using molecules of the invention to alter genetic activities of nucleic acids involved in pathological conditions.

(57) Abrégé

L'invention concerne une technique d'identification de molécules d'acides nucléiques contenant des éléments d'acides nucléiques à activité cis. L'invention concerne également une méthode permettant d'isoler des facteurs de liaison d'acides nucléiques, ainsi que des méthodes d'identification de composés constituant des analogues des éléments d'acides nucléiques à activité cis, de composés constituant des analogues des facteurs de liaison des acides nucléiques, de composés liant sélectivement les éléments d'acides nucléiques à activité cis et de composés déplaçant sélectivement la liaison entre un facteur de liaison d'acides nucléiques et un élément d'acide nucléique à activité cis ou entre plusieurs facteurs de liaison d'acides nucléiques. De surcroît, l'invention concerne d'une part, une méthode permettant de déterminer l'état de liaison d'un acide nucléique, et d'autre part plusieurs molécules d'acides nucléiques contenant des éléments d'acides nucléiques à activité cis, plusieurs éléments d'acides nucléiques à activité cis isolés, et plusieurs facteurs de liaison d'acides nucléiques isolés. L'invention concerne enfin des méthodes de traitement d'états pathologiques utilisant les molécules de l'invention pour modifier l'activité génétique des acides nucléiques impliqués dans ces états pathologiques.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1 /68		(11) International Publication Number: WO 00/04196
A2		(43) International Publication Date: 27 January 2000 (27.01.00)
<p>(21) International Application Number: PCT/US99/15860</p> <p>(22) International Filing Date: 13 July 1999 (13.07.99)</p> <p>(30) Priority Data: 60/092,697 14 July 1998 (14.07.98) US 09/165,794 2 October 1998 (02.10.98) US</p> <p>(71) Applicant (for all designated States except US): CISTEM MOLECULAR CORPORATION [US/US]; 5310 Eastgate Mall, San Diego, CA 92064 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KAUFFMAN, Stuart, A. [-/US]; 15 Montecito, Santa Fe, NM 87501 (US). BALLIVET, Marc [-/CH]; 15, rue Muzy, CH-1207 Geneva (CH).</p> <p>(74) Agents: GAY, David, A. et al.; Campbell & Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: CIS ACTING NUCLEIC ACID ELEMENTS AND METHODS OF USE</p> <p>(57) Abstract</p> <p>The invention provides a method of identifying nucleic acid molecules that contain cis acting nucleic acid elements. Also provided is a method of isolating nucleic acid binding factors. The invention also provides methods of identifying compounds that are cis acting nucleic acid element analogs, compounds that are nucleic acid binding factor analogs, compounds that selectively bind cis acting nucleic acid elements and compounds that selectively displace binding between a nucleic acid binding factor and a cis acting nucleic acid element or between nucleic acid binding factors. Also provided is a method of determining a binding state of a nucleic acid. Pluralities of isolated nucleic acid molecules containing cis acting nucleic acid elements, of isolated cis acting nucleic acid elements and of isolated nucleic acid binding factors are also provided. The invention further provides methods of treating pathological conditions using molecules of the invention to alter genetic activities of nucleic acids involved in pathological conditions.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GR	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Descripti n

5

10

15

20

25

30

35

40

45

50

55

CIS ACTING NUCLEIC ACID ELEMENTS AND METHODS OF USEBACKGROUND OF THE INVENTION

This invention relates to the identification and use of cis acting nucleic acid elements that bind to nucleic acid binding factors to regulate genetic activities of nucleic acids.

All living creatures store information in nucleic acid molecules called DNA or RNA that encode structural and regulatory proteins. The collective behavior of nucleic acids and proteins constitutes and controls normal cell and organismal life cycles. Nucleic acids and proteins also act as causative agents in, or response factors to, pathological conditions.

Transcription of DNA into RNA, translation of RNA into proteins and other genetic events such as nucleic acid synthesis, sorting, processing, repair and degradation, are regulated by a variety of specialized nucleic acid binding factors. Nucleic acid binding factors bind to specific sequences present on the nucleic acid molecules they regulate, called cis acting nucleic acid elements. These nucleic acid binding factors, bound to their specific cis acting nucleic acid elements, are able to interact with other cellular factors to modulate specific genetic events. The binding of a nucleic acid binding factor to a cis acting nucleic acid element, or its ability to interact with other factors that mediate genetic events, or both, can be regulated in response to signals transmitted into the cell from the cell exterior.

As an example, regulatory proteins called "transcription factors" bind to cis acting nucleic acid

5 elements on genomic DNA at sites known as "promoters" and
"enhancers" present at variable distances from the site
of initiation of transcription of the genes they
10 regulate. The enhancer sequences and adjacent nucleic
5 acid sequences, together with their bound transcription
factors, are able to bend to contact the transcriptional
complex bound to the promoter. Such contact can either
15 enhance or reduce expression of the regulated gene.

The human genome, which stores the genetic
10 information of a human cell as DNA, is estimated to
20 contain about 100,000 genes. Each of these genes and the
RNAs they encode is likely to have multiple cis acting
nucleic acid elements that bind to corresponding nucleic
25 acid binding factors to regulate gene expression. These
15 cis acting nucleic acid elements, and the factors that
bind them, are potential targets for therapeutic drugs
that could be used to modulate gene expression.
Determining which cis acting nucleic acid elements are
30 bound under different conditions can also be used to
20 characterize and monitor the genetic responses of a cell
under normal, pathological or experimental conditions.

35 Current methods of identifying cis acting nucleic
acid elements have several disadvantages. Most of these
methods require prior identification of either the
40 25 nucleic acid that is regulated, or the corresponding
regulatory nucleic acid binding factor, or both. For
example, once a nucleic acid has been identified,
adjacent sequences, which are predicted to contain cis
45 acting nucleic acid elements, can be isolated and
30 subsequences therefrom are tested for cis activities.
Alternatively, once a nucleic acid binding factor has
been isolated, the sequences to which it binds can be
50 identified. Other methods, which are limited to

identifying transcriptional enhancer elements, involve cloning random nucleic acid sequences upstream of a reporter gene and observing expression of the reporter gene product.

At present, however, there is no broadly applicable method to identify cis acting nucleic acid elements without prior identification of the regulated nucleic acid or of the regulatory nucleic acid binding factor. There is also no rapid and efficient method to simultaneously identify a plurality of cis acting nucleic acid elements.

Thus, there exists a need for a method of rapidly and efficiently identifying cis acting nucleic acid elements. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The invention provides a method of identifying nucleic acids containing cis acting nucleic acid elements. The method consists of contacting a diverse population of nucleic acid binding factors with a diverse population of isolated nucleic acid molecules under conditions that allow the nucleic acid binding factors to selectively bind the nucleic acids. The nucleic acids that bind the nucleic acid binding factors are identified and are characterized as nucleic acids containing cis acting nucleic acid elements. The method simultaneously provides for the isolation of nucleic acid binding factors that selectively bind the isolated nucleic acid molecules.

The invention also provides methods of identifying compounds that are cis acting nucleic acid element

5
10
15
20
25
30
35
40
45
50
55

analog, compounds that are nucleic acid binding factor analogs, and compounds that selectively bind cis acting nucleic acid elements. The invention further provides methods to identify compounds that selectively displace binding between a nucleic acid binding factor and a cis acting nucleic acid element or between nucleic acid binding factors.

The invention further provides a plurality of isolated nucleic acid molecules that each contain one or more cis acting nucleic acid elements. Also provided is a plurality of isolated cis acting nucleic acid element analogs. The isolated nucleic acid molecules containing cis acting nucleic acid elements and the isolated cis acting nucleic acid element analogs in the pluralities can be bound to nucleic acid binding factors. A plurality of isolated nucleic acid binding factors is also provided.

The invention also provides a method of determining a binding state of a nucleic acid. The method consists of contacting a nucleic acid with a plurality of isolated cis acting nucleic acid elements under conditions that allow nucleic acid binding factors bound to the nucleic acid to bind to the isolated cis acting nucleic acid elements. The isolated cis acting nucleic acid elements that bind the nucleic acid binding factors are identified and characterize the binding state of the nucleic acid.

The invention further provides a method of treating a pathological condition in an individual. The method consists of administering to the individual an effective amount of a therapeutic agent that selectively alters the ability of a cis acting nucleic acid element

5 to regulate a genetic activity of a nucleic acid involved
in the pathological condition. Also provided is a method
of treating a pathological condition in an individual by
10 contacting a cell of the individual with an effective
5 amount of a targeting construct that includes a cis
acting nucleic acid element and targeting sequences. The
targeting construct is taken up by the cell and inserted
15 by homologous recombination into a nucleic acid involved
in the pathological condition so as to alter a genetic
10 activity of the nucleic acid.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to the
25 identification and use of cis acting nucleic acid
elements.

15 Cis acting nucleic acid elements and the binding
30 factors that selectively bind such elements regulate the
genetic circuitry that controls all aspects of cell and
organismal growth and development. Cis acting nucleic
acid elements regulate genetic activities that underlie
35 20 growth and development, including, for example,
replication of nucleic acids and expression of both
nucleic acids and proteins. Therefore, cis acting
nucleic acid elements and their corresponding nucleic
40 acid binding factors are targets for therapeutic agents
25 that modulate cell or tissue growth, development,
pathogenesis, regeneration or repair by altering,
enhancing or reducing the genetic activity of the nucleic
45 acids they regulate.

Compounds that selectively bind cis acting nucleic
30 acid elements, that selectively bind nucleic acid binding
50 factors, or that selectively displace binding of a cis

5 acting nucleic acid element to its binding factor, are
all potential therapeutic agents that can modulate a
genetic activity of a nucleic acid regulated by the cis
10 acting nucleic acid element. Furthermore, isolated cis
5 acting nucleic acid elements and the corresponding
nucleic acid binding factors can themselves be used as
therapeutic agents to selectively modulate a genetic
15 activity. Cis acting nucleic acid elements can also be
used to identify and isolate a nucleic acid or group of
10 nucleic acids that are modulated by the cis acting
nucleic acid elements, such as a gene or a family of
20 genes involved in a particular disease or that regulate a
particular stage of development.

25 In one embodiment, the invention provides methods
15 of identifying cis acting nucleic acid elements. The
methods are advantageous in allowing rapid and efficient
identification of cis acting nucleic acid elements
without prior knowledge of the nucleic acid sequences
30 they regulate or of the corresponding nucleic acid
binding factors that bind the cis acting elements. The
20 methods provide a means of simultaneously identifying cis
acting nucleic acid elements that modulate a genetic
35 activity of a plurality of nucleic acids. Cis acting
nucleic acid elements can be used as therapeutic agents
25 or to screen for therapeutic agents, as well as to
40 diagnose disease.

45 In another embodiment, the invention provides
methods for identifying nucleic acid binding factors that
bind to cis acting nucleic acid elements without prior
30 knowledge of either the cis acting nucleic acid elements
they bind or the nucleic acid sequences they regulate.
The methods are advantageous in providing a means of
50 simultaneously identifying nucleic acid binding factors

5
10
15
20
25
30
35
40
45
50
55

that modulate a genetic activity of a plurality of nucleic acids. Nucleic acid binding factors can be used as therapeutic agents or to screen for therapeutic agents that selectively target a nucleic acid or group of nucleic acids.

In yet another embodiment, the invention provides methods of identifying compounds that are analogs of cis acting nucleic acid elements or of nucleic acid binding factors, or that displace binding of cis acting nucleic acid elements to nucleic acid binding factors. The methods are advantageous in that they provide a rapid and efficient means of screening for compounds that can be used as therapeutic agents to modulate a genetic activity of a nucleic acid or group of nucleic acids involved in disease.

In another embodiment, the invention is directed to a method of determining the binding state of one or a plurality of nucleic acids. The binding of a nucleic acid binding factor to a cis acting nucleic acid element is generally required for its regulatory activity. Therefore, the binding state of a nucleic acid or a plurality of nucleic acids is a means of characterizing the activation state of the nucleic acid or plurality of nucleic acids. Such a characterization can be used for a variety of purposes such as, for example, diagnosing pathological conditions or monitoring the efficacy of therapeutic procedures.

As used herein, the term "cis acting nucleic acid element" refers to a single-stranded or double-stranded RNA or DNA sequence that can be selectively bound by nucleic acid binding factors to regulate one or more genetic activities of a nucleic acid sequence present on

5 the same molecule. Cis acting nucleic acid elements are
present in all organisms, including prokaryotes,
eukaryotes and viruses. For example, cis acting nucleic
10 acid elements are present in yeast, animals, plants,
5 bacteria and viruses.

Cis acting DNA elements are found in a variety of
15 different types of DNA including, for example, genomic,
mitochondrial and chloroplast DNA. Cis acting DNA
elements are also located at a variety of locations on
10 chromosomes. For example, cis acting DNA elements are
20 located at diverse locations within chromosomes, such as
within transcription units or at the domain boundaries of
transcriptional units, as well as at the centromeres,
kinetochores and telomeres of chromosomes. Cis acting
25 DNA elements can regulate a variety of genetic activities
including, for example, enhancing, attenuating or
repressing transcription of a structural or regulatory
gene or operon. A cis acting DNA element can also
30 regulate, for example, replication, repair, packaging,
20 modification, restriction or degradation of a DNA
sequence.

35 Cis acting DNA elements also include nucleic acid
elements that modulate the assembly or structural
integrity of DNA. A specific example of a cis acting DNA
40 25 element that modulates the assembly or structural
integrity of DNA is a boundary element that selectively
binds to scaffold proteins and serves to define
transcriptional domains of chromatin. Additionally, cis
45 acting DNA elements are present at kinetochores,
30 centromeres or telomeres of chromosomes and modulate the
assembly and structural integrity of DNA.

5
10
15
20
25
30
35
40
45
50
55

Cis acting RNA elements are also found in a variety of different types of RNAs including, for example, messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small nuclear or small cytoplasmic RNA (snRNA or scrRNA) and viral RNA. Cis acting RNA elements can regulate a variety of genetic activities including, for example, RNA translation, replication, splicing, editing, intracellular transport, localization, degradation and reverse transcription.

20
25
30
35
40
45
50
55

The types of cis acting nucleic acid elements present in nucleic acids vary depending on the cell and nucleic acid type. For example, transcription of eukaryotic DNA involves a variety of cis acting nucleic acid elements such as promoter elements, enhancer elements and response elements. Certain of these cis acting nucleic acid elements, for example, TATA boxes, are found in a majority of genes. Other cis acting nucleic acid elements, for example, hormone response elements, are characteristic of genes that are coordinately regulated. Some cis acting nucleic acid elements bind to nucleic acid binding factors in a tissue-specific or temporal manner, whereas others are constitutively bound by nucleic acid binding factors. Although individual cis acting nucleic acid elements can be involved in the regulation of many different nucleic acids, a particular combination of cis acting nucleic acid elements can be specific for one or only a limited number nucleic acids.

30
35
40
45
50
55

A cis acting nucleic acid element can be localized within the nucleic acid sequence it regulates, or upstream or downstream thereof. A cis acting nucleic acid element can be a contiguous nucleic acid sequence,

5 or a multi-partite sequence. For example, a nucleic acid
binding factor or complex of factors can bind to a
continuous cis acting nucleic acid element or to two or
10 more discontinuous nucleic acid sequences that are in
5 close proximity due to folding or looping of the
polynucleotide, that together form a nucleic acid
element. A cis acting nucleic acid element is generally
15 from about 4 to about 100 nucleotides in length, and is
more typically from about 6 to about 25 nucleotides in
10 length.

20 The methods of the invention are applicable to the
identification and use of cis acting nucleic acid
elements of a wide variety of nucleic acid types and
sizes, and from any organism. The methods of the
25 invention also allow the identification and use of cis
15 acting nucleic acid elements or combinations of cis
acting nucleic acid elements that modulate any regulatory
or structural genetic activity, and that modulate any
30 subset of nucleic acids that is of interest.

20 As used herein, the term "selective binding" or
35 "selectively binds," when used in connection with binding
between a cis acting nucleic acid element and either a
nucleic acid binding factor or a compound, refers to
binding with substantially higher affinity to a nucleic
40 25 acid having a sequence that is substantially similar to
the sequence of a particular cis acting nucleic acid
element than to a nucleic acid that lacks substantial
similarity to the sequence of a particular cis acting
45 nucleic acid element. The degree or extent of nucleic
30 acid sequence similarity required for selective binding
of a nucleic acid binding factor or compound to a
particular cis acting nucleic acid element depends on,
50 for example, the length and sequence composition of the

5
10
15
20
25
30
35
40
45
50
55

cis acting nucleic acid element and the nature of the binding interaction. Such selective binding can be determined either qualitatively or quantitatively by known methods, such as by competition with nucleic acids of similar or different sequences to the cis acting nucleic acid element.

15
20
25
30
35
40
45
50
55

Selective binding between a nucleic acid binding factor and a compound refers to binding with substantially higher affinity to a substantially similar binding factor or compound than to an unrelated binding factor or compound. Selective binding between a nucleic acid binding factor and a compound can similarly be determined by, for example, competition for, or displacement of, binding with substantially similar binding factors and compounds, as compared with binding factors and compounds that lack substantially similarity. Selective binding between a nucleic acid binding factor and a compound that is a cis acting nucleic acid element analog can further be determined by an ability of a nucleic acid containing a sequence that is substantially similar to a cis acting nucleic acid element to compete for binding with the analog compound for the binding factor, such that the analog compound is selectively displaced.

25
30
35
40
45
50
55

As used herein, the term "diverse population of isolated nucleic acid molecules" refers to a composition comprising a plurality of different isolated polynucleotide nucleic acid molecules that potentially contain cis acting nucleic acid elements. The diverse population of nucleic acids used in the methods of the invention can be of a variety of different types, structures and topology. The choice of nucleic acid type, structure and topology will depend on the need and

5
10
15
20
25
30
35
40
45
50
55

desired result. For example, the diverse populations of nucleic acids of the invention can include double-stranded or single-stranded DNA or RNA, as well as linear, circular or branched nucleic acid molecules.

5
10
15
20
25
30
35
40
45
50
55

The term "isolated," when used in reference to isolated nucleic acid molecules, is intended to mean that the nucleic acid molecules are present in a form or state different from how they are found in nature. Similarly, the term "isolated," when used in reference to isolated nucleic acid binding factors, is intended to mean that the nucleic acid binding factors are present in a form or state different from how they are found in nature. For example, the isolated molecules can be different than populations found in nature in that they are substantially purified and therefore are free of molecules other than nucleic acids or other than nucleic acid binding factors. Such molecules can also be different than molecules found in nature in that they are, for example, produced or expressed by recombinant means or synthesized by chemical means. Such recombinantly or chemically produced molecules therefore do not contain some or many of the normal cellular components as they are found in nature or as they are isolated from natural sources and can also differ in multiplicity or homogeneity from populations of molecules found in nature. Furthermore, such molecules can also be different than molecules found in nature in that they are bound or immobilized, with or without cellular constituents, on a filter or solid support. Isolated molecules can also be different from the state or form found in nature in that they are detectably labeled or contain non-native nucleic acid sequences.

5
10
15
20
25
30
35
40
45
50
55

A population of different isolated nucleic acid molecules can be prepared, or obtained, that is of any diversity that is appropriate for a particular application of a method of the invention. A population of nucleic acids of low diversity can contain, for example, 2, 3, 4, 5, 6, 7, 8, 9, between about 10 and 20, between about 21 and 80, or between about 81 and 200 different nucleic acid molecules. For certain applications of the method, it may be preferable to begin with a population of nucleic acids of moderate diversity, containing, for example, between about 200 and 10^3 , preferably greater than about 10^4 , more preferably greater than about 10^5 different nucleic acid molecules. If desired, using currently available methods, it is possible to synthesize a population of isolated nucleic acid molecules of high diversity, containing, for example, between about 10^6 and 10^8 different nucleic acid molecules, preferably between about 10^9 and 10^{11} different nucleic acid molecules, most preferably about 10^{13} different nucleic acid molecules. As an example, a population that includes all possible molecules of between 5 and 20 nucleotides in length, including each of the four naturally occurring nucleotides at each position, would have approximately $4^5 + 4^6 + 4^7 + \dots + 4^{20}$ or approximately 10^{13} different nucleic acid molecules. Such a population of about 10^{13} 20 different nucleic acid molecules inherently includes all possible cis acting nucleic acid elements of up to about 20 nucleotides in length.

30
35
40
45
50
55

A diverse population of isolated nucleic acid molecules can be of completely random composition or of partially or completely known composition, so long as some nucleic acid sequences within the population are different. One skilled in the art would be able to

5 determine the extent of diversity and degree of
randomness required for a particular application of the
method.

10 A diverse population of isolated nucleic acid
5 molecules includes nucleic acid molecules potentially
containing cis acting nucleic acid elements. Depending
15 on the application of the method, a diverse population of
isolated nucleic acid molecules can include single-
stranded or double-stranded RNA or DNA molecules, or any
20 combination thereof. The isolated nucleic acid molecules
in the diverse population can be from about 4 to about
1000 nucleotides in length and can include molecules of
the same or of varying lengths. If desired, some or all
25 of the isolated nucleic acid molecules can include, or be
15 flanked at one or both ends by, known sequences, such as
sequences homologous to oligonucleotide primers for the
polymerase chain reaction (PCR), sequences containing
restriction sites, or detectable sequences.

20 As used herein, the term "nucleic acid binding
factor" is a factor that selectively binds a cis acting
35 nucleic acid element to modulate a genetic activity of a
nucleic acid or group of nucleic acids. Modulation can
include, for example, enhancing, repressing or
25 attenuating the regulation of a nucleic acid. Nucleic
acid binding factors include, for example, transcription
40 factors, replication factors, translation factors,
restriction and modifying factors, structural and
assembly factors, and other molecules involved in
45 30 regulating one or more genetic activities of a nucleic
acid sequence. Nucleic acid binding factors also include
factors involved in the structural integrity of chromatin
or chromosomes, such as, for example, scaffold proteins

5 and other factors that selectively bind to boundary elements, kinetochores, centromeres and telomeres.

10 A nucleic acid binding factor can interact covalently or non-covalently with other factors to form a
5 complex that binds a cis acting nucleic acid element. The factors within such a binding complex are also
15 included within the term "nucleic acid binding factor." Some nucleic acid binding factors within a complex of
nucleic acid binding factors can contact a cis acting
10 nucleic acid element directly. Other nucleic acid
20 binding factors within a complex of nucleic acid binding factors do not contact a cis acting nucleic acid element
directly, but can contact one or more other nucleic acid
binding factors. Disrupting the interaction between two
25 or more nucleic acid binding factors within a complex, or
between nucleic acid binding factors and a cis acting
nucleic acid element, will alter the ability of the cis
30 acting nucleic acid element to modulate a genetic
activity of the nucleic acid it regulates.

20 A nucleic acid binding factor can be a polypeptide
35 or a polypeptide that is modified, for example, by phosphorylation or addition of one or more carbohydrates,
nucleotides, nucleic acids, cofactors or lipids. A
nucleic acid binding factor can also be a non-
40 25 proteinaceous molecule, such as a lipid, carbohydrate or
nucleic acid, or any combination thereof.

45 As used herein, the term "diverse population of nucleic acid binding factors" is intended to mean a
composition containing a plurality of different nucleic
30 acid binding factors. The greater the number of
different factors within the population, the greater the
50 diversity of the population. A population of nucleic
acid binding factors can be of low diversity for certain

5 applications of the method. For example, a population of
nucleic acid binding factors of low diversity can
include, for example, 2, 3, 4, 5, 6, 7, 8, 9, between
10 about 10 and 20, between about 21 and 50, or between
5 about 51 and 100 different nucleic acid binding factors.
A population of nucleic acid binding factors of higher
diversity can include more than about 100, more than
15 about 10^3 , or more than about 10^4 different nucleic acid
binding factors. As with the diverse populations of
10 isolated nucleic acid molecules, the members within a
diverse population of nucleic acid binding factors can be
20 known, unknown or partially known so long as some of the
factors are different. One skilled in the art would be
able to determine the size and extent of diversity in a
15 population of nucleic acid binding factors required to
25 practice a particular embodiment of the invention.

A diverse population of nucleic acid binding
30 factors can be a population of nucleic acid binding
factors that is bound to nucleic acids, or unbound. For
20 example, a population of nucleic acid binding factors
bound to nucleic acids can be a cellular nucleic acid
35 preparation that contains nucleic acid binding factors.
Such a preparation can be, for example, a chromatin
preparation, a hnRNA preparation, an mRNA preparation, or
25 other nucleic acid preparation that includes nucleic acid
binding factors, depending on the type and function of
40 cis acting nucleic acid elements and nucleic acid binding
factors that are desired to be obtained. A population of
unbound nucleic acid binding factors can be, for example,
45 30 a population of nucleic acid binding factors eluted from
a nucleic acid preparation, or a cellular extract or
subset thereof.

As used herein, the term "diverse population of compounds" refers to a plurality of different molecules that potentially includes therapeutic compounds that can be used to selectively bind to cis acting nucleic acid elements, to nucleic acid binding factors, or to both. Therefore, a diverse population of compounds can include analogs of cis acting nucleic acid elements, analogs of nucleic acid binding factors, and molecules that selectively displace the binding between a cis acting nucleic acid element and its corresponding binding factor. Such compounds can be naturally occurring macromolecules, such as polypeptides, nucleic acids, carbohydrates or lipids. However, derivatives, analogs and mimetics of these macromolecules, as well as organic compounds, including polymers and small organic compounds, can also selectively bind a cis acting nucleic acid element or a nucleic acid binding factor.

The extent of diversity of a population of compounds required for a particular application of methods of the invention can be determined by those skilled in the art. Generally, the greater the diversity, the larger the likelihood of identifying a compound that binds a cis acting nucleic acid element or a nucleic acid binding factor, or that displaces binding between a cis acting nucleic acid element and a nucleic acid binding factor. A population of compounds of moderate diversity can readily be produced or obtained that contains greater than about 10^5 different compounds, more preferably greater than about 10^7 different compounds. A highly diverse population of compounds that contains greater than about 10^9 , preferably greater than about 10^{11} , more preferably greater than about 10^{13} different compounds, can also be used in a method of the invention and can be readily produced or obtained. A

5 less diverse population of compounds can also be
advantageous, for example, if the type of compounds that
are likely to bind are known or can be predicted based
10 on, for example, information about the sequence or
5 structure of the cis acting nucleic acid element, the
nucleic acid binding factor, or the binding interaction
between them.

15 A diverse population of compounds can include, for
example, naturally occurring nucleic acids and modified
10 nucleic acids that contain non-naturally occurring
20 nucleoside analogs or linkages. Such modifications can
be advantageous, for example, for increasing resistance
to chemical or enzymatic degradation. Various
25 modifications that increase the stability of nucleic
15 acids are known in the art and include, for example,
phosphotioate linkages. Methods of producing diverse
populations of natural and modified nucleic acids are
known in the art.

30 A diverse population of compounds that potentially
20 includes therapeutic agents that target cis acting
nucleic acid elements or nucleic acid binding factors can
35 also include libraries of peptides, carbohydrates or
synthetic organic molecule. Peptide libraries can
include, for example, diverse populations of chemically
40 synthesized peptides and peptidomimetic molecules.
25 Peptide libraries can also include populations of
peptides generated by recombinant means, such as phage
display or other recombinant methodologies by which a
45 peptide is or can be associated with the nucleic acid
30 which encodes it. Peptide and peptidomimetic libraries
of high diversity can be obtained commercially or can be
produced by methods known in the art. A diverse
50 population of compounds that potentially includes

5 therapeutic agents that target cis acting nucleic acid
elements or nucleic acid binding factors can be a
carbohydrate-based combinatorial library, such as an
10 oligosaccharide and glycoconjugate library. Diverse
5 populations of small synthetic molecules, prepared by
combinatorial chemistry methods, are also commercially
available or can be produced by means known in the art.
15 For example, a diverse population of organic molecules
that share one or more common structural features but
10 vary in reactive groups can be routinely produced. Any
of these libraries of compounds, if desired, can be
20 synthesized or immobilized onto a solid support or
detectably tagged by methods known in the art to provide
a means of detection.

25 15 As used herein, the term "binding state" refers to
the condition or degree of binding of cis acting nucleic
acids by nucleic acid binding factors. Modulation,
30 including activation, repression and attenuation of the
genetic properties of a nucleic acid by a cis acting
20 nucleic acid element often requires binding of a nucleic
acid binding factor to the cis acting nucleic acid
35 element. Therefore, the binding state of a nucleic acid
is a reflection or measurement of the type, degree, or
extent of regulation of the nucleic acid.

40 25 Determination of a "binding state" can be either
qualitative or quantitative. For certain applications,
it may be sufficient to determine whether one or a
plurality of nucleic acids is or is not bound by any
45 nucleic acid binding factor or by a particular nucleic
30 acid binding factor. For other applications, it may be
desirable to determine to what degree or extent a nucleic
acid is bound by a nucleic acid binding factor. For
50 example, it may be desirable to determine the percentage

5 of nucleic acids that are bound by a nucleic acid binding
factor, or to determine the affinity of a binding
interaction. For certain determinations of the binding
10 state, it may also be desirable to identify the nucleic
5 acid binding factor that binds the nucleic acid.

Depending on the particular nucleic acids and
15 isolated cis acting nucleic acid elements used in an
application of the method, the term "binding state" can
refer to, for example, the "transcriptional state," the
10 "replication state," the "translational state" or other
20 genetic properties of a nucleic acid. Furthermore, the
term "binding state" can refer to a binding state of a
single nucleic acid or group of nucleic acids. The term
"binding state" can also refer to the binding state of a
25 15 cell, group of cells, or tissue. For example, the term
"binding state" can characterize the transcriptional
activation state of a gene or a family of genes in a cell
type of interest.
30

The invention provides a method of identifying a
20 nucleic acid containing a cis acting nucleic acid
35 element. The method involves contacting a diverse
population of nucleic acid binding factors with a diverse
population of isolated nucleic acid molecules under
conditions that allow nucleic acid binding factors to
40 25 selectively bind the nucleic acids. The nucleic acids
that selectively bind the nucleic acid binding factors
are identified and are characterized as nucleic acids
containing a cis acting nucleic acid element.
45

As described previously, cis acting nucleic acid
30 elements selectively bind nucleic acid binding factors
and modulate one or more genetic activities of nearby
50 nucleic acids. Any method of altering the interaction

5 between a cis acting nucleic acid element and a nucleic
acid binding factor can be used to alter a genetic
activity of the regulated nucleic acid. For example,
10 selective binding between a cis acting nucleic acid
5 element and a nucleic acid binding factor can be
displaced by a molecule that selectively binds to either
the cis acting nucleic acid element or the nucleic acid
15 binding factor. Such a molecule can be, for example, a
nucleic acid containing a cis acting nucleic acid
10 element, a nucleic acid binding factor, or other
compound. Similarly, selective binding between a
20 compound and a nucleic acid binding factor can be
selectively displaced by either a nucleic acid binding
factor or a nucleic acid containing a cis acting nucleic
15 acid element. Likewise, selective binding between a
25 compound and a cis acting nucleic acid element can be
selectively displaced by either a cis acting nucleic acid
element or a nucleic acid binding factor. The molecules
30 that are displaced and the molecules that effect the
20 displacement, or any combination of these molecules, can
be identified and isolated by a method of the invention.
Therefore, by providing methods of distinguishing between
35 nucleic acids that are bound by nucleic acid binding
factors or other compounds, and nucleic acids that are
25 unbound, the methods of the invention can be applied to
the identification and isolation of cis acting nucleic
40 acid elements, nucleic acid binding factors and compounds
that bind either cis acting nucleic acid elements or
nucleic acid binding factors.

45 30 The cis acting nucleic acid elements, nucleic acid
binding factors and compounds identified by the methods
of the invention can be used for therapeutic purposes to
alter the activity of one or a plurality of nucleic acids
50 involved, for example, in disease, development, tissue

5 repair or regeneration. The invention can be used with
large, diverse populations of isolated nucleic acid
molecules or nucleic acid binding factors, or smaller
10 biased populations that contain, for example, nucleic
5 acid sequences or nucleic acid binding factors that are
known or predicted to be localized to a particular
genomic region, or that are known or predicted to be
15 indicative of a particular normal or pathological
condition.

10

20 A diverse population of isolated nucleic acid
molecules can be produced or obtained by a variety of
means known in the art. Both the diversity of the
population and the type of nucleic acids will depend on
15 the particular application of the method. Methods of
25 producing a diverse population of isolated nucleic acid
molecules are well known, and include, for example,
biochemical and recombinant methods as well as by
chemical synthesis. For example, a diverse population of
30 isolated nucleic acid molecules can be obtained by
20 cleaving an appropriate cellular or viral source of
nucleic acids into smaller fragments by enzymatic,
35 mechanical or chemical means. Fragments of approximately
the desired size are isolated by fractionation methods
25 known in the art, such as column chromatography or
electrophoresis through a gel. As described previously,
40 such fragments can be, for example, from about 4 to about
1000 nucleotides in length.

45 Subregions of the genome are particularly useful in
30 applications where it is desirable to identify cis acting
nucleic acid elements that regulate genes or gene
families known or predicted to be involved in growth,
development or pathogenesis. Therefore, a source of
50 double-stranded DNA that can be fragmented to form a

5
10
15
20
25
30
35
40
45
50
55

diverse population of isolated nucleic acid molecules can be, for example, genomic DNA or a fragment therefrom, such as a chromosome or chromosomal arm, one or more DNA structural or transcriptional domains, or one or more genes. Methods of isolating such DNA preparations are known in the art. A source of single-stranded DNA can be, for example, any of the above double-stranded DNAs that either prior to or after fragmenting has been denatured by methods known in the art, including heating and alkali treatment. Similarly, sources of RNA, such as hnRNA, mRNA and viral RNA can be produced and fragmented or fractionated by means known in the art. If desired, known nucleic acid sequences can be attached to one or both ends of the isolated nucleic acid molecules.

15
20
25
30
35
40
45
50
55

A diverse population of isolated nucleic acid molecules of various lengths and sequence compositions can also be produced by synthetic means. For example, single-stranded DNA or RNA molecules can be synthesized using automatic nucleic acid synthesizers. Such molecules can include predetermined degenerate or random sequences at all or some positions. Methods of synthesis that result in random, degenerate or partially degenerate nucleic acid sequences are known in the art (see, for example, U.S. Patent No. 5,723,323, incorporated herein by reference). If desired, known nucleic acid sequences can be attached to one or both ends of the isolated nucleic acid molecules. Depending on the need, single-stranded nucleic acids can be rendered double-stranded and purified by means known in the art.

30
35
40
45
50
55

The size of the diverse population of isolated nucleic acid molecules can vary depending on the need and desired efficiency for identifying a particular cis acting nucleic acid element. The larger and more diverse

5 the population, the greater the probability of obtaining
productive interactions and, therefore, the greater the
likelihood of obtaining one, or many, cis acting nucleic
10 acid elements. It is not necessary, however, to use
5 large diverse populations to practice the methods of the
invention. For example, populations of isolated nucleic
acid molecules that are smaller in size or diversity but
15 which are known or expected to contain cis acting nucleic
acid elements can similarly be used and result in the
10 identification of cis acting nucleic acid elements. For
example, it is possible to identify cis acting nucleic
20 acid elements from a population as small as two nucleic
acids. Those skilled in the art will know, or can easily
determine, the size and diversity of the population of
15 isolated nucleic acid molecules to be used depending on
25 the desired number and types of cis acting nucleic acid
elements to be identified.

30 A population of at least about 10^{13} different
nucleic acids that includes all possible molecules of
20 between 5 and 20 nucleotides in length can readily be
obtained by synthetic means. For example, by
35 synthesizing oligonucleotides having each of the four
naturally-occurring nucleotides at each position, a
diverse population of approximately $4^5 + 4^6 + 4^7 + \dots + 4^{20}$ or
25 approximately 10^{13} different candidate sequences can be
40 obtained. Such a population would include virtually
every possible sequence of between 5 and 20 nucleotides
in length, including virtually every possible cis acting
nucleic acid element of between 5 and 20 nucleotides in
45 30 length.

Longer nucleic acid sequences can also be directly
synthesized, or can be generated by combining shorter
50 sequences. Methods of combining shorter sequences are

5 known in the art. For example, single-stranded nucleic
acids with regions of complementarity can be allowed to
anneal under annealing conditions known in the art. A
10 polymerization reaction can then be performed to extend
5 each strand of the oligonucleotide using the overhanging
portion of the complementary strand as a template.
Optionally, the strands can be separated, reannealed, and
15 extension repeated until a diverse population of the
desired length is achieved.

10 As a further example, multiple short double
20 stranded DNA sequences can be combined to form longer
sequences using enzymatic methods known in the art. If
desired, restriction enzyme sites can be designed in the
flanking sequences or within the nucleic acids containing
25 the potential cis acting nucleic acid elements.
Following restriction digestion, random combinations of
nucleic acid sequences can be ligated together in a
ligation reaction. Alternatively, random combinations of
30 double-stranded nucleic acids with blunt ends can be
20 ligated together in a ligation reaction.

35 If desired, the isolated nucleic acid molecules
can be flanked on one or both sides with nucleic acid
sequences with desired properties. For example, an
isolated nucleic acid molecule can have a restriction
40 25 enzyme binding consensus sequence or a sequence
complementary to a primer for amplification by the
polymerase chain reaction (PCR) at one or both ends.
These flanking nucleic acid sequences can be used, for
45 example, to combine or extend nucleic acids as described
30 above, to amplify nucleic acids sequences by PCR either
before or after incubation with nucleic acid binding
factors, or to identify or isolate nucleic acids that
50

selectively bind to nucleic acid binding factors or compounds.

A diverse population of nucleic acid binding factors is also provided, and is used to contact the diverse population of isolated nucleic acid molecules. Depending on need, the diverse population of nucleic acid binding factors can vary in size and diversity. The larger and more diverse the population, the greater the probability of obtaining productive interactions and, therefore, the greater the likelihood of obtaining one, or many cis acting nucleic acid elements bound to nucleic acid binding factors. It is not necessary, however, to use large diverse populations to practice the methods of the invention. For example, nucleic acid binding factor populations that are smaller in size or diversity but which are known or expected to contain nucleic acid binding factors can similarly be used. Using a population containing as few as two nucleic acid binding factors in the methods of the invention, it is possible to identify one or more cis acting nucleic acid elements. Those skilled in the art will know, or can easily determine, the size and diversity of the nucleic acid binding factor population to be used depending on the desired number and types of cis acting nucleic acid elements and nucleic acid binding factors to be identified.

Depending on need, such as, for example, the type of cis acting nucleic acid element and nucleic acid binding factor one intends to identify, the population of nucleic acid binding factors can be biased to include, for example, nucleic acid binding factors that normally bind to particular types of cis acting nucleic acid elements, that are normally found in particular cell

types, that respond to particular extracellular stimuli, or that are localized to particular chromosomal or subchromosomal locations.

A source of nucleic acid binding factors can be, for example, a cell or subcellular extract obtained by biochemical fractionation procedures known in the art. A cytoplasmic extract, for example, can be a source of a diverse population of nucleic acid binding factors that bind, for example, mRNA including, for example, nucleic acid binding factors involved in genetic processes such as translation, editing, degradation, and the like. A nuclear extract, for example, can be a source of a diverse population of nucleic acid binding factors that bind, for example, hnRNA and single- and double-stranded nuclear DNA including, for example, replication factors, transcription factors, splicing factors and boundary element binding factors. A mitochondrial extract can be a source of a diverse population of nucleic acid binding factors that bind, for example, mitochondrial DNA. A chloroplast extract can be a source of a diverse population of nucleic acid binding factors that bind, for example, chloroplast DNA.

A source of nucleic acid binding factors can also be nucleic acid binding factors bound to nucleic acids, either within a cell or obtained from a cell. For example, a source of nucleic acid binding factors can be cytoplasmic, mitochondrial or nuclear RNA or DNA. A source of nucleic acid binding factors can also be a preparation of nucleic acids bound to nucleic acid binding factors that is isolated from other cellular components. For example, where it is desirable to identify cis acting nucleic acid elements involved in a particular disease or developmental state, nucleic acid

5 binding factors bound to nucleic acids from a particular
genomic or chromosomal location known to be involved in
the disease can be used as a source of binding factors.
10 Therefore, a diverse population of nucleic acid binding
5 factors bound to nucleic acids can be, for example, bound
to chromatin, a chromosome, a chromosome arm, a
transcriptional domain, a gene family or a gene,
15 depending on the application of the method. A
transcriptional domain refers to a loop or segment of DNA
10 that extrudes from chromomeres and that is bounded by cis
acting boundary elements. Such a structural domain is
20 often an actively transcribed region of DNA.

If desired, nucleic acid binding factors can be
released from a nucleic acid preparation and used to
25 15 contact the diverse population of isolated nucleic acid
molecules. Methods of releasing nucleic acid binding
factors bound to a nucleic acid in a nucleic acid
30 preparation can be determined for a particular nucleic
acid preparation by those skilled in the art and include,
20 for example, varying the salt concentration or pH of the
solution.

35 Diverse populations of nucleic acid binding
factors can also be obtained by recombinant
methodologies. One skilled in the art would be able to
40 25 determine an appropriate source of nucleic acids to
express to obtain nucleic acid binding factors for a
particular application of the method. For example, cDNA
libraries are available or can be produced by known
45 methods from genes expressed by any desired tissue or
30 cell source, or in response to any pathogenic or normal
stimulus.

5
10
15
20
25
30
35
40
45
50
55

Depending on the types of cis acting nucleic acid elements one wishes to identify, nucleic acid binding factors can be obtained as described above from cells from different tissues or at different developmental stages. Nucleic acid binding factors can also be obtained from either normal or diseased cells, or following exposure of cells to external stimuli such as therapeutic drugs.

10
20
25
30
35
40
45
50
55

Once the starting populations of isolated nucleic acid molecules and nucleic acid binding factors have been selected and obtained, the populations are combined under conditions that allow the nucleic acid binding factors to selectively bind to the isolated nucleic acid molecules containing cis acting nucleic acid elements. Binding conditions will vary depending on the type and source of nucleic acid binding factors and the type and source of nucleic acids, but can be readily determined. For example, since the affinity and specificity of interactions between nucleic acid binding factors and cis acting nucleic acid elements are generally dependent on the charge of both molecules, one can vary the salt concentration or pH of a buffer to differentially allow binding interactions of particular affinities.

40
45
50
55

Conditions that allow binding between nucleic acid sequences and nucleic acid binding factors are also designed to ensure that a sufficient concentration of nucleic acids and nucleic acid binding factors are present for a particular application. For example, in one embodiment of the invention, nucleic acid binding factors bound to nucleic acids in a nucleic acid preparation are contacted with a diverse population of isolated nucleic acids. The nucleic acid binding factors will equilibrate between being bound to the cis acting

5 nucleic acid elements present in the nucleic acid
preparation, and the cis acting nucleic acid elements
present in the diverse population of isolated nucleic
10 acid molecules. The distribution of nucleic acid binding
5 factors between being bound to cis acting nucleic acid
elements present in the nucleic acid preparation, and
being bound to cis acting nucleic acid elements in the
15 isolated population of nucleic acids will depend, for
example, on the ratio between the number of copies of the
10 corresponding cis acting nucleic acid elements present in
the nucleic acid preparation and the number of copies of
20 the corresponding cis acting nucleic acid elements in the
isolated population. An excess of a particular isolated
cis acting nucleic acid element to a cis acting nucleic
15 acid element present in the nucleic acid preparation
would shift the binding equilibrium toward preferential
binding to the isolated nucleic acid molecules. For
example, an excess of about 10 to 1, or about 10^3 to 1, or
30 about 10^6 to 10^{10} to 1 of isolated cis acting nucleic acid
20 elements to cis acting nucleic acid element present in
the nucleic acid preparation could be used in the
invention. However, smaller ratios can also be used
35 without substantially reducing the selectivity of the
interaction. The use of smaller ratios, including, for
25 example, equal amounts or less than an excess of isolated
cis acting nucleic acid elements compared to those in the
40 preparation can be advantageous, for example, when
selectively identifying high affinity interactions
between the cis acting nucleic acid element and nucleic
30 acid binding factors.

45
As an example, if a chromatin preparation is
contacted with a diverse population of isolated nucleic
acid molecules, the number of isolated nucleic acid
50 molecules is chosen so as to compete with the chromatin

5
10
15
20
25
30
35
40
45
50
55

for the chromatin-bound factors to a desired extent for a particular application. One skilled in the art could determine the number of copies of each member of the diverse population of isolated nucleic acid molecules required for a particular application of the method. Methods known in the art, such as the polymerase chain reaction, allow production of as many copies of a particular isolated nucleic acid sequence as desired.

10
20
25
30
35
40
45
50
55

After allowing isolated nucleic acid molecules to contact and bind nucleic acid binding factors, nucleic acids that selectively bind to nucleic acid binding factors are identified. These nucleic acids contain one or more cis acting nucleic acid elements. Any method for identifying nucleic acids that are selectively bound to nucleic acid binding factors can be used, including methods of physically separating bound and unbound nucleic acids, as well as methods of distinguishing between bound and unbound nucleic acids that do not require the physical separation of bound from unbound nucleic acids.

35
40
45
50
55

Methods of physically separating nucleic acids that are bound to binding factors from nucleic acids that are unbound are known in the art. For example, nucleic acids that are bound to nucleic acid binding factors and those that are unbound can be separated by virtue of size, shape, charge or density of the bound complex as compared to unbound nucleic acids. For example, nucleic acids bound to nucleic acid binding factors will pass through a chromatography column at a different rate than unbound nucleic acids. Appropriate chromatography resins can be determined by those skilled in the art for a particular application. Additionally, depending on the nature of the nucleic acid binding factor, a nucleic acid

bound to a nucleic acid binding factor can have a greater or lesser density than an unbound nucleic acid, and can be separated from unbound nucleic acids by known methods of density centrifugation. Furthermore, bound and unbound nucleic acids will have different electrophoretic mobilities, and can be separated by methods known in the art such as electrophoretic mobility shift assays (EMSA). If desired, the bound nucleic acids can be isolated, stored, amplified, sequenced or used as described below.

Furthermore, it is known that a nitrocellulose membrane will selectively retain double-stranded DNA bound to proteinaceous nucleic acid binding factors, but will allow unbound DNA to pass through the filter. Therefore, following binding of isolated nucleic acid molecules with nucleic acid binding factors, the binding reaction can be filtered through a nitrocellulose filter. DNAs that are bound to nucleic acid binding factors are retained on a nitrocellulose filter. These DNAs contain cis acting nucleic acid elements. If desired, the retained nucleic acids can be eluted from the nitrocellulose membrane and stored, amplified, sequenced or used as described below. One skilled in the art can also vary buffer conditions to selectively retain single-stranded nucleic acid sequences bound to nucleic acid binding factors on nitrocellulose filters while allowing unbound nucleic acid sequences to pass through the filters. The retained nucleic acids contain cis acting nucleic acid elements. One skilled in the art could also modify such as assay by, for example, varying the type of membrane, to selectively retain nucleic acids bound to non-proteinaceous nucleic acid binding factors.

Methods of distinguishing between nucleic acids that are bound to nucleic acid binding factors and those

5 that are unbound, which do not require the physical
separation of bound from unbound nucleic acids, are
similarly known in the art. A method of distinguishing
10 between bound nucleic acids and unbound nucleic acids
5 takes advantage of properties that distinguish bound
nucleic acids as compared to unbound nucleic acids such
as, for example, nuclease resistance. As one example of
15 the use of nuclease resistance to distinguish bound from
unbound nucleic acids, a diverse population of isolated
10 double-stranded DNA can be flanked, at one or both ends,
with a sequence containing the binding site of a
20 restriction enzyme that is known, or can be designed, to
cut at a site at a distance away from the binding site.
Both ends of the nucleic acid also contain sequences that
15 are complementary to PCR primers. Following binding
25 between isolated nucleic acid molecules and nucleic acid
binding factors, the reaction mixture is further
incubated with such a restriction enzyme under conditions
30 that allow cleavage of DNA at the restriction enzyme
20 cleavage site only if the cleavage site is not bound to a
nucleic acid binding factor. Thus, DNA that is unbound
is cleaved, and bound DNA is not cleaved. Uncleaved DNA
35 therefore retains PCR primer sites at both ends of the
cis acting nucleic acid element and can be amplified by
25 PCR, whereas cleaved DNA only has a single primer site
and can not be amplified by PCR. If desired, the nucleic
40 acid binding factor and restriction enzyme can be removed
by methods known in the art, such as by appropriately
varying the buffer conditions. A PCR reaction is then
30 performed, which amplifies only those nucleic acids that
45 were bound to nucleic acid binding factors. These
nucleic acids contain cis acting nucleic acid elements.

50 Restriction enzymes that cleave at a distance of
about 5 to about 30 nucleotides away from the binding

5 site are commercially available. Such enzymes include,
for example, BbvI, BcgI, BciVI, BpmI, BseRI, BsmFI, FokI,
10 HgaI, HphI, MboII, MnlI and SfaNI, each of which is
available from New England BioLabs, Inc. Using knowledge
5 of restriction enzyme structure, it is also possible to
design restriction enzymes that combine a desired binding
site specificity with a desired cleavage site specificity
15 and cleavage site distance.

For certain methods of distinguishing between
10 bound and unbound nucleic acids, it may be desirable to
detectably label either the diverse population of nucleic
acids or the diverse population of nucleic acid binding
factors. Detectable labels include moieties such as, for
25 example, enzymes, radioisotopes, fluorochromes,
chemiluminescent markers, and biotin, which can be
15 incorporated into isolated nucleic acid molecules and
nucleic acid binding factors, or incorporated by
metabolic labeling into nucleic acids and nucleic acid
30 binding factors *in vivo* or in cultured cells. A
detectable label can also be a tag that can be
20 specifically recognized by a binding moiety, such as, for
example, an antibody.
35

For certain applications of the method, such as
25 high-throughput screening for therapeutic compounds and
for diagnostic procedures, it is advantageous to provide
the diverse population of nucleic acids on a solid
support. The diverse population of nucleic acids can be
40 synthesized on, or subsequently attached to, solid
supports such as beads, pins, resins or chips. Nucleic
45 acids attached to solid supports can be contacted with
nucleic acid binding factors; those nucleic acid binding
factors that are not specifically bound to nucleic acids
50 are removed, and the nucleic acids, both bound and

5 unbound, remain attached to the solid support. The bound
nucleic acids can be detected, for example, by virtue of
the detectable label present in either the nucleic acid
10 or the nucleic acid binding factor, or by virtue of
5 another inherent detectable property, such as charge,
size or nuclease resistance, that distinguishes bound
from unbound nucleic acids.

15 For example, the fluorescence of a fluorescently
labeled nucleic acid can be quenched by binding to a
10 nucleic acid binding factor, and this quenching can be
20 detected. Similarly, the amount of chemiluminescent
signal or radioactivity of a nucleic acid that can be
detected can be altered by binding to a nucleic acid
25 binding factor. Additionally, binding of nucleic acid
15 binding factor can protect a nucleic acid from
degradation by nucleases, and the undegraded nucleic
acids can be detected by virtue of their detectable
30 labels.

It is not necessary to be able to directly isolate
20 a nucleic acid that is bound to a nucleic acid binding
35 factor in order to identify it, if the corresponding
sequence of the nucleic acid that was bound to the
binding factor is known. For example, nucleic acids can
be synthesized on solid supports in arrays, with nucleic
40 25 acids of known sequences present at known locations.
Therefore, any property that identifies selectively bound
nucleic acids from unbound nucleic acids in a diverse
population of nucleic acids present in an array of
45 nucleic acids can be used to identify cis acting nucleic
30 acid elements. Nucleic acid chips and automated
detection procedures are particularly advantageous in
high-throughput screening procedures for identifying cis
50 acting nucleic acid elements, nucleic acid binding

factors, and compounds that bind cis acting nucleic acid elements and nucleic acid binding factors.

Solid phase oligonucleotide synthesis methods are known in the art (see, for example, J. Weiler et al., *Anal. Biochem.* 243:218 (1996) and U. Maskos et al., *Nucleic Acids Res.* 20(7):1679 (1992); T. Atkinson et al., *Solid-Phase Synthesis of Oligodeoxyribonucleotides by the Phosphitetriester Method*, in *Oligonucleotide Synthesis* 35 (M.J. Gait ed., 1984), as are methods for synthesizing arrays of oligonucleotides (see, for example, United States Patent No. 5,474,796; International Publication No. WO 95/25116; Blanchard et al., "High-density oligonucleotide arrays" *Biosensors & Bioelectronics* 11(6/7):687-690 (1996)).

The above methods of distinguishing between nucleic acids that are bound to nucleic acid binding factors and those that are not can be used individually, or in any combination or order, to identify nucleic acids containing cis acting nucleic acid elements.

Once the sequences of one or a plurality of isolated nucleic acid molecules containing cis acting nucleic acid elements is determined, any desired set or subset thereof can be synthesized, using methods known in the art, and used in a variety of therapeutic, diagnostic and screening methods. The cis acting nucleic acid elements within the isolated nucleic acid molecules can be determined, if desired, by means known in the art. For example, known methods of nucleic acid "footprinting" can be used. A nucleic acid can be detectably labeled and contacted with a nucleic acid binding factor or population of nucleic acid binding factors. The nucleic acid is then partially digested with a nuclease. The

5 sequences that are protected from nuclease digestion by
the bound nucleic acid binding factor are the cis acting
nucleic acid elements.

10 If desired, the sequences of isolated cis acting
5 nucleic acid elements identified by a method of the
invention can be directly compared with cis acting
15 nucleic acid elements found in cellular or viral DNA or
RNA. Such comparison is advantageous, for example, in
determining the extent to which a cis acting nucleic acid
10 element identified by a method of the invention is
identical to a cis acting nucleic acid element found in
naturally occurring populations of nucleic acids. Such
comparison also advantageously allow the determination of
25 which nucleic acids are regulated by particular cis
15 acting nucleic acid elements. These regulated nucleic
acids can include previously unknown or uncharacterized
genes involved in disease or development, which can
themselves be used in therapeutic and diagnostic
30 procedures.

20 Several methods are known in the art that can be
used to compare sequences of isolated cis acting nucleic
35 acid elements to cis acting nucleic acid elements found
in cellular or viral DNA or RNA. For example, the
partial or complete genomic sequences of a variety of
40 25 different organisms, including humans, are available in
databases. These databases can be searched for identical
or substantially similar sequences to the cis acting
nucleic acid elements identified by a method of the
45 invention. The regulated genes can be identified and
30 produced by recombinant or synthetic means known in the
art.

5
10
15
20
25
30
35
40
45
50
55

Additionally, populations of nucleic acids cloned in, for example, phage, plasmid, cosmid or YAC libraries are available or can be prepared by methods known in the art. These libraries can be screened using methods known in the art, such as nucleic acid hybridization, to determine the cis acting nucleic acid elements and flanking sequences in the cellular or viral nucleic acids that are substantially similar to the cis acting nucleic acid elements identified by the methods of the invention.

10
15
20
25
30
35
40
45
50
55

Furthermore, the location of one or a plurality of cis acting nucleic acid elements within a particular cell compartment or within a particular chromosome can be advantageously used to characterize the cis acting nucleic acid elements and the nucleic acids they regulate. For example, depending on the starting population of isolated nucleic acid molecules and nucleic acid binding factors, several types of cis acting nucleic acid elements could be simultaneously identified. Therefore, by examining the location of hybridization of a cis acting nucleic acid element to the cellular nucleic acids, the type of cis acting nucleic acid element and the location of the regulated nucleic acids can be determined. For example, boundary elements, elements that bind telomeres and elements that bind transcription factors could be distinguished by knowing where each element mapped to the chromosomes. Similarly, RNA elements that are present in mRNA as compared to hnRNA could be distinguished by virtue of their intracellular location. Such methods of mapping nucleic acid sequences to particular nucleic acid locations are known in the art and include, for example, fluorescence *in situ* hybridization (FISH).

5
10
15
20
25
30
35
40
45
50
55

The methods of the invention for identifying and isolating cis acting nucleic acid elements that are bound to nucleic acid binding factors also simultaneously provide for the identification and isolation of nucleic acid binding factors that selectively bind cis acting nucleic acid elements. Therefore, the invention provides a method of isolating a nucleic acid binding factor. The method involves contacting a diverse population of nucleic acid binding factors with a diverse population of isolated nucleic acid molecules under conditions that allow nucleic acid binding factors to selectively bind nucleic acids, and isolating one or more nucleic acid binding factors that selectively bind one or more isolated nucleic acid molecules. The source and diversity of the populations of nucleic acid binding factors and isolated nucleic acid molecules can be determined by those skilled in the art, as described previously, based on the type and number of nucleic acid binding factors that it is desired to isolate in a particular application of the method.

Following contacting the populations of isolated nucleic acid molecules and nucleic acid binding factors, the isolated nucleic acid molecules that are selectively bound by nucleic acid binding factors are separated from unbound nucleic acids. As described previously, methods are known in the art to physically separate nucleic acids that are bound to nucleic acid binding factors from nucleic acids that are unbound. Such methods include, for example, filtration, chromatography, electrophoresis and centrifugation. The selectively bound nucleic acid binding factors are dissociated from the nucleic acids they bind and are isolated. Methods of dissociating nucleic acid binding factors from nucleic acids are known

in the art and include, for example, varying the salt or detergent concentration or the pH of the buffer.

Once isolated, the nucleic acid binding factor of interest can be produced in large quantity from a diverse population of nucleic acid binding factors using, for example, its corresponding cis acting nucleic acid element or other binding agent, such as a specific antibody, as an affinity reagent. Furthermore, if a nucleic acid binding factor is a protein, the sequence of the encoding gene can be readily determined and the nucleic acid binding factor can be recombinantly produced.

The site of interaction between a nucleic acid binding factor and other binding factors in a binding complex, and the site of interaction between a nucleic acid binding factor and its corresponding cis acting nucleic acid element, also can be determined using methods known in the art. Knowledge about these sites of interaction can be used to design therapeutic compounds that alter or disrupt these interactions.

The genetic circuitry of cells and viruses controls cell and organismal behavior, including, for example, proliferation, differentiation and pathogenicity. Therefore, being able to modulate the control properties, dynamics or behavior of the genetic circuitry or to modify the genetic circuitry directly, of a host cell or a pathogen in a controlled way, in order to alter nucleic acids that mediate these processes, can be advantageous for therapy. For example, modulating the control properties, dynamics or behavior of the genetic circuitry of a cell, or modifying the genetic circuitry directly, can be used to modulate the proliferation,

5 differentiation, susceptibility to disease or
susceptibility to drugs of the cell, depending on the
particular therapeutic application. Modulating the
10 control properties, dynamics or behavior of the genetic
5 circuitry of a pathogen, or modifying its genetic
circuitry directly, can also be used to modulate the
infectivity, pathogenicity or drug resistance of the
15 pathogen.

The identification of cis acting nucleic acid
10 elements and nucleic acid binding factors provides a
20 means of rapidly identifying compounds that can alter the
control properties, dynamics or behavior of the genetic
circuitry of a cell or virus for therapeutic purposes.
The identification of cis acting nucleic acid elements
25 that modulate a genetic activity of nucleic acids
involved in a pathological condition also provides a
means of inserting, removing or replacing the cis acting
30 nucleic acid elements to directly modify the genetic
circuitry of a cell for therapeutic purposes.

20 The methods of the invention provide for the
35 identification of therapeutic compounds that can target
any nucleic acid or group of nucleic acids of interest
that contain one or more cis acting nucleic acid
elements. Such therapeutic compounds include, for
40 25 example, analogs of cis acting nucleic acid elements,
analogs of nucleic acid binding factors, compounds that
bind to either cis acting nucleic acid elements or
nucleic acid binding factors or both, as well as cis
45 acting nucleic acids and nucleic acid binding factors
30 themselves. These therapeutic compounds can, for
example, compete with an endogenous cis acting nucleic
acid element for binding to a nucleic acid binding
50 factor, or compete with a nucleic acid binding factor for

5 binding with its corresponding cis acting nucleic acid
element. These compounds can also physically disrupt the
binding of an endogenous cis acting nucleic acid element
10 to its corresponding nucleic acid binding factor or
5 disrupt the binding between two or more nucleic acid
binding factors.

15 Altering the regulation of nucleic acids
associated with disease can prevent or treat disease.
Compounds that target cis acting nucleic acid elements
10 and nucleic acid binding factors involved in particular
20 diseases can be identified and used to enhance, inhibit,
alter, antagonize or mimic the regulation of a nucleic
acid known or predicted to be associated with disease.
For example, cis acting nucleic acid elements or nucleic
25 15 acid binding factors that are known or expected to
modulate one or a plurality of nucleic acids involved in
cancer, degenerative diseases, genetic disorders, immune
disorders, bacterial and viral infectious diseases and
30 the like, can be used in the methods described below to
20 identify specific therapeutic compounds that will target
the corresponding regulated nucleic acid. These
35 therapeutic compounds can beneficially alter a genetic
activity of the nucleic acid, such as, for example, its
structural integrity, transcription, translation, or
25 replication, so as to ameliorate or prevent the disease.

40 The isolated nucleic acid molecules or the nucleic
acid binding factors, or both, in the exemplary methods
of identifying therapeutic compounds described below, can
45 be biased populations that include cis acting nucleic
30 acid elements or nucleic acid binding factors that are
known or predicted to regulate nucleic acids involved in
a disease. The compounds so obtained would be expected
50 to preferentially include compounds that are selective
for the nucleic acids involved in the particular disease.

5
10
15
20
25
30
35
40
45
50
55

Alternatively, the starting populations can be large, random populations of nucleic acids and nucleic acid binding factors. In the latter case, it would be expected that a library of compounds would be obtained, only a few of which would be selective for any particular nucleic acid or nucleic acid binding factor. However, the library of compounds obtained using the methods of the invention can readily be screened to determine which subset of compounds alters the regulation of any nucleic acid of interest.

Methods of screening to determine that a compound alters the regulation of a particular nucleic acid can be determined by those skilled in the art depending on the nucleic acid and its properties. For example, the affinity and selectivity of a compound for binding to a particular cis acting nucleic acid element or nucleic acid binding factor could be determined using a binding competition assay. Likewise, the effect of a compound on the regulation of a nucleic acid could be determined by examining the expression of the mRNA or protein encoded by the regulated nucleic acid. Furthermore, the effect of the compound on a property of a cell, such as growth, differentiation or apoptosis, that depends on the expression of the gene, could be determined.

Compounds that selectively bind to nucleic acid binding factors, such that they can be selectively displaced by isolated nucleic acid molecules, are analogs of cis acting nucleic acid elements. Such compounds are potential therapeutic agents that can alter a genetic activity modulated by a cis acting nucleic acid element of which the compound is an analog. Therefore, the invention provides a method of identifying a cis acting nucleic acid element analog. The method involves

5 contacting a diverse population of nucleic acid binding
factors with a diverse population of compounds under
conditions that allow the compounds to selectively bind
10 the nucleic acid binding factors. One or more of the
5 nucleic acid binding factors selectively bound to one or
more of the compounds is contacted with one or more
isolated nucleic acid molecules under conditions that
15 allow one or more of the isolated nucleic acid molecules
to selectively displace one or more of the selectively
10 bound compounds. The isolated nucleic acid molecules or
the nucleic acid binding factors, or both, can correspond
20 to or regulate nucleic acids that are known or expected
to play a role in a disease of interest. The displaced
compounds are identified and characterized as cis acting
15 nucleic acid element analogs. Such a method further
provides for the identification of one or more of the
isolated nucleic acid molecules that selectively
displaces one or more of the selectively bound compounds.
30 An isolated nucleic acid molecule that selectively
20 displaces one or more of the selectively bound compounds
is characterized as a nucleic acid containing a cis
acting nucleic acid element.

35 Compounds that selectively bind to isolated
nucleic acid molecules or to nucleic acid binding factors
25 in a nucleic acid binding factor complex, such that they
can be displaced by selectively binding to nucleic acid
40 binding factors, are analogs of nucleic acid binding
factors. Such compounds are potential therapeutic agents
that can alter a genetic activity modulated by a cis
45 acting nucleic acid element that binds a nucleic acid
30 binding factor of which the compound is an analog.
Therefore, the invention also provides a method of
identifying nucleic acid binding factor analogs. In one
50 embodiment, the method consists of contacting a diverse

5 population of compounds with a diverse population of
isolated nucleic acid molecules under conditions that
allow the compounds to selectively bind the isolated
10 nucleic acid molecules. One or more of the isolated
5 nucleic acid molecules selectively bound to one or more
of the compounds is contacted with one or more nucleic
acid binding factors under conditions that selectively
15 displace one or more of the selectively bound compounds
from one or more of the bound nucleic acids. The
10 isolated nucleic acid molecules or the nucleic acid
binding factors, or both, can correspond to or regulate
20 nucleic acids that are known or expected to play a role
in a disease of interest. The displaced compounds are
identified, and are characterized as nucleic acid binding
15 factor analogs. The method further provides for the
identification of one or more nucleic acid binding
factors that displaces one or more of the selectively
bound compounds.

30 In a further embodiment of the above method,
20 compounds that selectively bind either to cis acting
nucleic acid elements or to nucleic acid binding factors
in a nucleic acid binding factor complex or to both can
35 be simultaneously identified. The method involves
contacting a diverse population of compounds with a
25 diverse population of isolated nucleic acid molecules
bound to nucleic acid binding factors under conditions
40 that allow the compounds to selectively bind to either
the isolated nucleic acid molecules or to the nucleic
acid binding factors. One or more of the isolated
45 nucleic acid molecules selectively bound to nucleic acid
binding factors and selectively bound to one or more
compounds is contacted with one or more nucleic acid
binding factors under conditions that allow one or more
50 of the nucleic acid binding factors to selectively

5
10
15
20
25
30
35
40
45
50
55

displace one or more of the selectively bound compounds. The isolated nucleic acid molecules or the nucleic acid binding factors, or both, can correspond to or regulate nucleic acids that are known or expected to play a role in a disease of interest. The displaced compounds are identified, and are characterized as nucleic acid binding factor analogs. The displaced compounds can further be characterized to determine whether they bind to a cis acting nucleic acid element or to a nucleic acid binding factor in a complex of nucleic acid binding factors.

Compounds that selectively bind to cis acting nucleic acid elements can also be used as therapeutic agents to alter the activity of nucleic acids modulated by cis acting nucleic acid elements. Therefore, the invention also provides a method of identifying compounds that bind cis acting nucleic acid elements. The method involves contacting a plurality of isolated nucleic acid molecules, wherein each nucleic acid comprises one or more cis acting nucleic acid elements, with a diverse population of compounds under conditions that allow the compounds to selectively bind the isolated nucleic acid molecules. The compounds that selectively bind one or more isolated nucleic acid molecules containing one or more cis acting nucleic acid elements are identified.

As described previously, the isolated nucleic acid molecules containing cis acting nucleic acid elements can correspond to nucleic acids that are known or expected to play a role in a disease of interest, or can be a large, random population. A compound identified by the method can be tested for its ability to bind a cis acting nucleic acid element of interest by direct or indirect assays known in the art. Such assays include, for

5 example, binding assays, reporter assays, and functional
assays that measure the effect of introduction of the
10 compound on a property of the cell.

The invention also provides a method of
5 identifying compounds that selectively displace binding
of a cis acting nucleic acid element to a nucleic acid
15 binding factor or of a nucleic acid binding factor to
another nucleic acid binding factor. The method involves
contacting a plurality of isolated nucleic acid molecules
20 selectively bound to nucleic acid binding factors, with a
diverse population of compounds under conditions that
allow the compounds to selectively displace one or more
of the selectively bound nucleic acid binding factors
25 from one or more of the bound nucleic acids or from one
or more of the bound nucleic acid binding factors in the
binding factor complex. The isolated nucleic acid
molecules containing cis acting nucleic acid elements or
30 the nucleic acid binding factors, or both, can correspond
to or regulate nucleic acids that are known or expected
to play a role in a disease of interest. The isolated
nucleic acid molecules can be selected to each contain
35 one or more cis acting nucleic acid elements. The
compounds that selectively displace one or more of the
bound nucleic acid binding factors from one or more of
25 the bound nucleic acids or from one or more of the bound
nucleic acid binding factors in the binding factor
40 complex are identified. Such a compound can, for
example, bind to the site of interaction between the cis
acting nucleic acid element and the nucleic acid binding
45 factor and be, therefore, either a cis acting nucleic
acid element analog or a nucleic acid binding factor
analog. Such a compound can also, for example, bind to
50 the site of interaction between two or more nucleic acid
binding factors within a nucleic acid binding factor

5
10
15
20
25
30
35
40
45
50
55

complex. Alternatively, such a compound can bind elsewhere on the cis acting nucleic acid element or elsewhere on one or more of the nucleic acid binding factors, so long as binding between a nucleic acid binding factor and either a cis acting nucleic acid element or another nucleic acid binding factor is selectively modified or displaced by binding of the compound.

The methods of the invention described above can be used to identify compounds that are selective for many different nucleic acids as well as compounds that target only a very limited number of nucleic acids. As described previously, some of the cis acting nucleic acid elements that regulate a particular nucleic acid will likely also be involved in the regulation of numerous other nucleic acids. Therefore, a therapeutic compound that binds to that cis acting nucleic acid element or its corresponding nucleic acid binding factor may have an effect on the regulation of many nucleic acids other than the intended target nucleic acid. However, a particular combination of cis acting nucleic acid elements will be relatively specific for a particular nucleic acid or family of nucleic acids. Therefore, the invention also provides for the identification of therapeutic agents that are specific for one or several nucleic acids by using isolated nucleic acid molecules that include a combination of cis acting nucleic acid elements in the methods described above. The cis acting nucleic acid elements in the combination of cis acting nucleic acid elements can be linked by the naturally occurring intervening sequences. Alternatively, so as to provide for a convenient overall nucleic acid length, non-native intervening sequences can be introduced between the cis acting nucleic acid elements. Using the methods

5
10
15
20
25
described above, therapeutic compounds that selectively bind to the combination of cis acting nucleic acid elements, or compounds that selectively bind to or displace the combination of nucleic acid binding factors, can be identified.

15
20
25
30
35
40
45
50
55
The above methods of identifying compounds that can be used as therapeutic agents take advantage of the ability to distinguish between nucleic acids that are selectively bound to particular compounds or binding factors, and nucleic acids that are either unbound or bound to different compounds or binding factors. Any method of distinguishing bound from unbound nucleic acids can be used in the above methods of identifying therapeutic compounds that bind cis acting nucleic acid elements and nucleic acid binding factors, such as those described previously. Such methods can be automated by, for example, providing arrays of isolated nucleic acid molecules on solid supports. Similarly, arrays of compounds on solid supports can be provided. The compounds, the nucleic acid binding factors, or the nucleic acids can be detectably labeled by methods known in the art. Additionally, isolated nucleic acid molecules that are bound to particular compounds can differ from unbound nucleic acids or nucleic acids bound to different compounds or nucleic acid binding factors in their ability to be retained on filters such as nitrocellulose filters, and can differ in charge, size, density, electrophoretic mobility and resistance to nucleases.

Compounds, nucleic acid binding factors, and isolated nucleic acids can be removed from the molecules they selectively bind for further characterization, if desired. Alternatively, pools of such molecules can be

repeatedly subdivided until one or a plurality of selectively bound or selectively displaced molecules is isolated or identified.

The invention also provides a plurality of isolated nucleic acid molecules, wherein each isolated nucleic acid molecule contains one or more cis acting nucleic acid elements. Such a plurality of isolated nucleic acid molecules containing cis acting nucleic acid elements can contain, for example, between about 2-5 different isolated nucleic acid molecules, or between about 6-10 different isolated nucleic acid molecules. The plurality of isolated nucleic acids can also contain between about 11-20 different isolated nucleic acid molecules or greater than about 20 different isolated nucleic acid molecules. The number of isolated nucleic acid molecules will depend on the type of nucleic acids in the plurality and the intended use of the plurality. These nucleic acids can be attached to a solid support, if desired, and advantageously used for automated screening and diagnostic procedures.

A plurality of isolated nucleic acid molecules containing cis acting nucleic acid elements can be identified and obtained, for example, by the methods described above. The plurality can be produced in abundance by, for example, chemical synthesis or by amplification by the polymerase chain reaction. If desired, isolated cis acting nucleic acid elements can be synthesized with various amounts of adjacent sequences. These adjacent sequences can be used, for example, in the detection, amplification, cloning or further modification of the sequences. As described above, a plurality of isolated nucleic acid molecules containing cis acting nucleic acid elements can be, for example, a set of

5 isolated transcription factor binding elements, such as
enhancers and promoters; a set of isolated replication
factor binding elements, such as origins of replication;
10 a set of isolated restriction or modification enzyme
5 binding sites; or any other set of nucleic acid cis
acting elements that regulates a desired genetic activity
of nucleic acids.

15 As described above, a plurality of isolated
nucleic acid molecules containing cis acting nucleic acid
10 elements can be characteristic of, for example, a
20 particular cell type, a particular disease or
developmental state of a cell, or a particular response
to external stimuli. A plurality of nucleic acids
25 containing cis acting nucleic acid elements can also be
15 characteristic of a particular subset of cellular nucleic
acids, such as a chromosomal region that maps to a
disease locus.

30 The invention also provides a plurality of
isolated nucleic acid molecules bound to nucleic acid
20 binding factors, wherein each isolated nucleic acid
35 molecule contains one or more cis acting nucleic acid
elements. Such a plurality of isolated nucleic acid
molecules bound to nucleic acid binding factors can
contain, for example, between about 2-5 different
40 25 isolated nucleic acid molecules, or between about 6-10
different isolated nucleic acid molecules. The plurality
of isolated nucleic acids can also contain between about
11-20 different isolated nucleic acid molecules or
45 greater than about 20 different isolated nucleic acid
30 molecules. The number of isolated nucleic acid molecules
bound to nucleic acid binding factors will depend on the
type of nucleic acids and nucleic acid binding factors in
50 the plurality and the intended use of the plurality.

5
10
15
20
25
30
35
40
45
50
55

These nucleic acids or nucleic acid binding factors can be attached to a solid support, if desired, and advantageously used for automated screening and diagnostic procedures. As described above, such a plurality can be used, for example, to identify therapeutic compounds that can selectively modify or displace the binding of a cis acting nucleic acid element to a nucleic acid binding factor or that can selectively modify or displace the binding between two or more nucleic acid binding factors.

The invention also provides a plurality of isolated nucleic acid binding factors that includes at least about 15 different isolated nucleic acid binding factors. The plurality of isolated nucleic acid binding factors can also contain between about 16-25 different isolated nucleic acid binding factors, preferably between about 26-50 different isolated nucleic acid binding factors, and more preferably greater than about 51 different isolated nucleic acid binding factors. The number of isolated nucleic acid binding factors in the plurality will depend on the type of nucleic acid binding factors in the plurality and the intended use of the plurality. If desired, the plurality of isolated nucleic acid binding factors can be attached to a solid support, and advantageously used for automated screening and diagnostic procedures.

The invention also provides a plurality of cis acting nucleic acid analogs. Such a plurality of cis acting nucleic acid analogs can include between about 2-5 different isolated cis acting nucleic acid element analogs, or between about 6-10 different isolated cis acting nucleic acid element analogs. The plurality of cis acting nucleic acid analogs can also contain ,

5
10
15
20
25
30
35
40
45
50
55

between about 11-20 different isolated cis acting nucleic acid element analogs or greater than about 20 different isolated cis acting nucleic acid element analogs. These analogs can be compounds obtained, for example, by the methods of the invention and are potential therapeutic agents that can be used to alter the interactions between the cis acting nucleic acid elements they mimic and nucleic acid binding factors.

The invention further provides a plurality of nucleic acid binding factor analogs. Such a plurality of cis acting nucleic acid analogs can include between about 2-5 different isolated cis acting nucleic acid element analogs, or between about 6-10 different isolated cis acting nucleic acid element analogs. The plurality of isolated cis acting nucleic acid element analogs can also contain, between about 11-20 different isolated cis acting nucleic acid element analogs or greater than about 20 isolated cis acting nucleic acid element analogs. These analogs can be compounds obtained, for example, by the methods of the invention and are potential therapeutic agents that can be used to alter the interactions between the nucleic acid binding factors they mimic and either cis acting nucleic acid elements or other nucleic acid binding factors within a complex of nucleic acid binding factors.

As described previously, the invention provides for the identification of cis acting nucleic acid elements and nucleic acid binding factors that regulate or modulate the genetic activity of nucleic acids that cause or are involved pathological conditions. The methods of the invention also provide for the identification of therapeutic compounds, including cis acting nucleic acid elements, nucleic acid binding

factors and their analogs, that can be used therapeutically to alter the genetic activity of these nucleic acids involved in pathological conditions.

Therefore, the invention provides a method of treating a pathological condition in an individual. The method involves administering to an affected individual an effective amount of one or more therapeutic agents that selectively alter the ability of one or more cis acting nucleic acid elements to regulate a genetic activity of one or more nucleic acids involved in the pathological condition.

A pathological condition mediated by the dysregulation of one or more nucleic acids can be treated by a method of the invention. For example, a therapeutic compound can be administered to either selectively increase or selectively decrease a genetic activity of one or more nucleic acids that is dysregulated in the cells of the diseased individual, as required. Similarly, a pathological condition mediated by a virus or bacteria can be treated by administering a compound that selectively alters a genetic activity of the pathogen.

The nucleic acids involved in the pathological condition are known in the art or are determined, for example, as described below using the knowledge that cis acting nucleic acid elements are present in the vicinity of actively transcribed genes. The appropriate genetic activity to target using a method of the invention can be determined by those skilled in the art and will depend on the underlying disease mechanism for a particular disease. As one example, cancer can be treated by administering a therapeutic compound of the invention that selectively targets oncogene transcription. As a

5 further example, a viral infection can be treated by
administering a compound of the invention that
10 selectively targets viral replication.

15 A therapeutic agent can be formulated into a
5 pharmaceutical composition that is convenient for
delivering the agent to the target cells and to the
10 target location within the cell, such as, for example,
the nucleus or cytoplasm. Such pharmaceutical
15 compositions contain the therapeutic agent together with
a pharmaceutically acceptable carrier. Pharmaceutically
20 acceptable carriers are well known in the art and include
aqueous solutions such as water, physiologically buffered
saline or other solvents or vehicles such as glycols,
25 glycerol, oils such as olive oil or injectable organic
15 esters and liposomes.

30 A pharmaceutically acceptable carrier can contain
physiologically acceptable compounds that act, for
example, to stabilize or increase the absorption of the
therapeutic agent. Such physiologically acceptable
20 compounds include, for example, carbohydrates, such as
35 glucose, sucrose or dextrans, antioxidants, such as
ascorbic acid or glutathione, chelating agents, low
molecular weight proteins or other stabilizers or
excipients. One skilled in the art would know that the
40 25 choice of a pharmaceutically acceptable carrier,
including a physiologically acceptable compound, depends,
for example, on the nature of the therapeutic agent and
on the route of administration.

45 The therapeutic agent also can be incorporated, if
30 desired, into liposomes, which consist of phospholipids
or other lipids, and are nontoxic, physiologically
50 acceptable and metabolizable carriers that are relatively
simple to make and administer. Targeting of a

therapeutic agent encapsulated in liposomes to a cell or tissue in an individual can be passive or active.

Passive targeting, for example, utilizes the tendency of liposomes to accumulate in cells of the

reticuloendothelial system (RES) and in organs such as the liver, which contain sinusoidal capillaries. Active targeting, in comparison, involves alteration of the liposome by coupling a specific ligand such as a monoclonal antibody, a sugar, a glycolipid or a protein such as a ligand for a receptor expressed by the target cells.

A nucleic acid therapeutic agent, or an encoded polypeptide, can be contained in a vector known in the art, such as a plasmid, cosmid, or viral vector. Viral vectors such as retroviral vectors, adenovirus vectors, herpes simplex virus vectors, vaccinia virus and the like are particularly useful for the administration of nucleic acid therapeutic agents and encoded polypeptides. The choice of vector and route of administering the vector will depend, for example, on the particular target cells, and can be determined by those skilled in the art.

A therapeutic agent that modulates genetic activities mediated by cis acting nucleic acid elements can be administered to an individual by various routes including, for example, orally or parenterally, such as intravenously, intramuscularly, subcutaneously, intraorbitally, intracapsularly, intraperitoneally, intrarectally intracisternally or by passive or facilitated absorption through the skin using, for example, a skin patch or transdermal iontophoresis, respectively. Furthermore, a therapeutic agent can be administered by injection, intubation, orally or topically, the latter of which can be passive, for

example, by direct application of an ointment or powder, or active, for example, using a nasal spray or inhalant.

Compounds identified as described above as therapeutic agents can be further modified using known methods so as to have, for example, enhanced stability or bioavailability, or to have optimal affinity for a cis acting nucleic acid element or a nucleic acid binding factor. A compound can also be modified to have positive or negative regulatory activities. For example, a compound that binds a cis acting nucleic acid element or a nucleic acid binding factor can be modified to include a transcriptional activation domain so as to selectively activate transcription of a gene. Similarly, a compound can be modified to include a domain that would, for example, cleave a nearby nucleic acid sequence or attenuate its transcription.

Identification of cis acting nucleic acid elements also allows alteration of the genetic circuitry of a cell by genetic modification. Genetic modification can be used, for example, to enhance, reduce or alter the expression of a nucleic acid or group of nucleic acids for therapeutic purposes. For example, a normal or altered copy of one or more cis acting nucleic acid elements can be introduced at a normal location or altered location within the genome of a cell, in order to modify the regulation of a nearby nucleic acid. The cis acting nucleic acid element can be, for example, responsive to an agent such as a hormone, growth factor, metal ion or antibiotic. Following insertion, the cis acting nucleic acid element confers regulation by the agent on the nucleic acid of interest. Similarly, a strong constitutive promoter or enhancer element or elements can be inserted in close proximity to a nucleic

5 acid of interest to constitutively increase the
expression of the nucleic acid. One or more cis acting
nucleic acid elements that normally regulate a nucleic
10 acid of interest can also be removed or replaced to alter
5 the regulation of the nucleic acid.

15 Therefore, the invention provides a method of
treating a pathological condition in an individual by
genetic modification. The method involves contacting a
cell of the individual with an effective amount of a
10 targeting construct that includes a cis acting nucleic
20 acid element and targeting sequences. The targeting
sequences correspond to a sequence of a nucleic acid
involved in the pathological condition. The targeting
construct is taken up by the cell and the cis acting
25 nucleic acid element is inserted by homologous
15 recombination into the nucleic acid involved in the
pathological condition so as to alter its genetic
30 activity.

Methods of inserting, removing and replacing
20 nucleic acid sequences at predetermined locations using
35 homologous recombination are known in the art and are
described, for example, in Yanez et al., Gene Therapy
5:149-159 (1998), which is incorporated herein by
reference. A targeting construct is prepared that
40 25 carries a segment of nucleic acid homologous to the
target nucleic acid as well as the desired modified
sequences. As described above, the modified sequences
can be, for example, a normal or altered copy of a cis
45 acting nucleic acid element that is to be introduced into
30 the target locus. Targeting constructs can be delivered
to the target cells by a variety of methods known in the
art, including, for example, electroporation,
50 microinjection, optoporation, polybrene, DMSO, DEAE-

5 dextran, liposome formulations, gene gun, polyamidoamine
dendrimers, synthetic peptides and combinations of these
agents and methods, such that they are taken up by the
10 target cells and incorporated into the target nucleic
5 acid. Large targeting constructs for homologous
recombination can be incorporated, for example, into
plasmids, cosmids or viral vectors, such as retroviral or
15 adenoviral vectors. Alternatively, chimeric DNA-RNA
oligonucleotides or small denatured DNA fragments, which
10 include the cis acting nucleic acid element flanked by
short targeting sequences, can also be used to introduce
20 a cis acting nucleic acid element into a cell at a
predetermined location in the genome.

25 Homologous recombination can be practiced either
15 ex vivo or in vivo, as needed, depending on the
therapeutic strategy. For example, cells of a variety of
lineages can be obtained from an individual, genetically
30 modified ex vivo by insertion, deletion or replacement of
one or more cis acting nucleic acid elements in order to
20 enhance expression of a beneficial gene or gene product
or reduce expression of a harmful gene or gene product,
35 and returned to the same or an immunologically matched
individual for therapeutic benefit. Similarly, a
targeting construct can be used to directly contact a
25 diseased cell within an individual, so as to be taken up
40 by the cell and inserted into the target nucleic acid
that is involved in the pathological condition so as to
alter its genetic activity.

45 Cis acting nucleic acid elements can also be used
30 to identify new genes that may be of importance in
diagnosing and treating disease. As known in the art and
described above, most structural and regulatory genes are
50 characterized by the presence of cis acting nucleic acid

5 sequences either within or adjacent to the gene.
Therefore the presence of a cis acting nucleic acid
element is indicative of a nearby gene. For example, cis
10 acting DNA elements can be detectably labeled and used to
5 hybridize to genomic libraries, or libraries of
subgenomic regions, using known methods. The genes so
identified can be sequenced and identified. This
15 procedure advantageously allows the simultaneous
identification of a plurality of genes that are modulated
10 by the same cis acting nucleic acid element or
combination of elements.

20
The invention also provides a method of
determining the binding state of a nucleic acid. The
15 method involves contacting a nucleic acid with a
25 plurality of isolated cis acting nucleic acid elements
under conditions that allow nucleic acid binding factors
bound to the nucleic acid to bind to the isolated cis
30 acting nucleic acid elements. The isolated cis acting
20 nucleic acid elements that bind to the nucleic acid
binding factors are identified, and characterize the
binding state of the nucleic acid.

35
Cellular nucleic acid binding factors can either
be constitutively bound to cis acting nucleic acid
25 elements or bind in response to appropriate extracellular
40 signals. For example, nucleic acid binding factors can
bind cis acting nucleic acid elements as a response to
hormones, growth and differentiation factors, stress,
pathological conditions, contact with neighboring cells
45 and other such stimuli. Therefore, the binding state of
30 a nucleic acid reflects its response to its environment
at the time of detection.

5
10
15
20
25
30
35
40
45
50
55

Depending on the desired application of the method, a binding state can be determined for any nucleic acid molecule in a single cell, group of cells or tissue of interest. The nucleic acid is obtained under conditions where it remains bound to its normal nucleic acid binding factors. For example, a chromatin preparation, hnRNA preparation, mRNA preparation, or any fraction of these or other preparations described above, can be obtained from a single cell, group of cells or tissue. By methods described above the nucleic acid preparation is contacted with a plurality of isolated cis acting nucleic acid elements under conditions such that the nucleic acid binding factors will bind to the isolated cis acting nucleic acid elements. As described above, such conditions can, if desired, involve an excess of isolated cis acting nucleic acid elements to shift the equilibrium to favor binding to the isolated cis acting nucleic acid elements.

A plurality of isolated cis acting nucleic acid elements useful in determining the binding state of a nucleic acid can include any type and combination of isolated cis acting nucleic acid elements, as described above, such as cis acting nucleic acid elements that regulate a particular group of genes or are found in a particular cell type of interest. The isolated cis acting nucleic acid elements that bind to nucleic acid binding factors can be distinguished from unbound nucleic acids by any of the methods described above including, for example, retention on nitrocellulose, protection from restriction digestion, and density or size fractionation.

Methods of determining which isolated cis acting nucleic acid elements are bound by a nucleic acid binding factor can also be automated. Automated detection is

5 particularly advantageous in rapidly and reproducibly
screening a large number of samples to determine their
binding state. For example, oligonucleotides
10 representing known cis acting nucleic acid elements can
5 be synthesized at known positions on arrays. Those cis
acting nucleic acid elements that are bound by nucleic
acid binding factors have altered properties, in
15 comparison with unbound cis acting nucleic acid elements,
as described previously, which allow them to be detected
10 by automated methods known in the art. The type, number,
pattern or extent of bound cis acting nucleic acid
20 elements is indicative of the binding state of the
nucleic acid being assayed.

25 A method of the invention can be used to diagnose
15 disease in an individual by comparing the binding state
of nucleic acids obtained from a cell, group of cells or
tissue of an individual suspected of having a disease
30 with the binding state of nucleic acids obtained from
similar cells from a normal individual. As a non-
20 limiting example, the binding state of one or more
nucleic acids can be used to diagnose cancer. Cancer is
35 characterized by the enhanced expression of genes that
promote the proliferation and metastasis of abnormal
cells, such as growth factors, proteases, angiogenic
25 factors, and the like. A method of the invention can be
used, therefore, to determine whether cis acting nucleic
40 acid elements that regulate the expression of such genes
are bound to nucleic acid binding factors in a particular
tissue. Cancer is also characterized by an increase in
45 DNA synthesis. Therefore, a method of the invention can
30 be used to determine whether cis acting nucleic acid
elements that regulate DNA synthesis are bound in a
particular tissue.

5
10
15
The binding state of nucleic acids can be determined, for example, before and after the administration of a therapeutic agent to monitor the consequences of therapy. For example, if a therapy is successful, the binding state of nucleic acids will more closely resembles the known normal binding state than the previous diseased state.

20
25
It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also included within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

15
30
Methods of identifying nucleic acids containing
a cis acting nucleic acid element
and methods of isolating nucleic acid binding factors

35
40
This example shows a method of identifying a nucleic acid containing a cis acting nucleic acid element, and a method of isolating a nucleic acid binding factor.

45
50
55
The method is practiced by biotinylating one strand of a double-stranded DNA bait at the 5' end. The core of the double-stranded DNA bait is random over about 20 base pairs. There are restriction sites at both ends of the bait, such as Sau3A1 sites. The DNA bait structure is prepared by chemical synthesis of the biotinylated strand, and enzymatic synthesis of the

complementary strand by elongation of the appropriate primer.

The design of the bait optionally includes sequences recognized by restriction enzymes that cut at a distance from their binding site, as described previously. Nuclear proteins, optionally histone-free, are purified in bulk from cell lines or tissue nuclei (animal or plant) by standard techniques. Alternatively, chromatin, optionally histone-free, is prepared from the same sources. As a further alternative, nuclear membrane fragments are prepared by flotation in sucrose gradient in order to focus the procedure on those transcription factor complexes and other DNA binding proteins that are associated with the nuclear membrane.

Bait DNA is incubated with nuclear proteins, chromatin or nuclear membrane fragments in a buffer medium containing protease inhibitors. The bait concentration is such that there are about 10^2 copies of every possible 20-mer random core, which corresponds to about 5 μ g of a 50 bp bait. The incubation variables are time, temperature and ionic strength, all of which may be varied to increase specificity. The incubation mix also contains synthetic double stranded DNA of low complexity (such as polydI-polydC) to compete for proteins that have a sequence-independent affinity for DNA (non-specific binding). The mixture is then passed through a nitrocellulose filter. This step ensures that only those bait DNAs that are complexed to proteins will be retained on the filter. Recovery of the bound bait DNA is effected by mild detergent elution followed by magnetic isolation with dynabeads coated with avidin. At this stage, several procedures can be conducted in parallel:

5
10
15
20
25
30
35
40
45
50
55

1) The washed beads are heated so as to denature the bound DNA and the beads are removed with a magnet, leaving the non-biotinylated strand in solution. This is amplified by PCR, using primers flanking the random sequences, one of which is derivatized in 5' with biotin. The amplified DNA is used as bait in a second round of selection, as above. The procedure may be reiterated.

2) Alternatively, washed beads are treated with restriction enzyme *Sau3A1*, so as to generate GATC sticky ends (which are also *hemi-BamH1* sites). The DNA is then ligated to an appropriate vector linearized with *BamH1* and dephosphorylated by alkaline phosphatase. Upon transformation into super-competent cells, 10^4 - 10^5 independent clones are obtained. These are grown in bulk and their inserts further amplified by PCR as above, one of the primers being biotinylated. Alternatively, several pools of 10^2 - 10^3 clones may be prepared and their inserts independently amplified. The amplified DNA is used as bait in one or more further rounds of selection, as in procedure 1).

3) As a further alternative, nuclear membrane preparations that have been incubated with bait DNA are floated again on a sucrose gradient, and the bait DNA specifically bound to this fraction eluted by mild detergent treatment, concentrated and purified on avidin beads and submitted to amplification and rescreening as above. This ensures the selective purification and amplification of those DNA sequences that bind to nucleic acid binding factors.

The specificity of the cis-element isolation procedure can be further increased by use of a

5 restriction enzyme whose recognition sequence is in the
fixed segment of the bait DNA and whose cutting site is
situated 10-20 bp to the side, designated type IIS
10 restriction enzymes. Digestion of the bait DNA-nuclear
5 protein complexes with such an enzyme selectively cleaves
naked bait DNA and spares protein-complexed DNA. The
cleaved DNA is not a substrate in the subsequent
15 amplification reaction, thereby increasing the
specificity of the procedure and selecting for
10 protein-DNA complexes whose off-rate is slow.

20 At this stage, the sets of selected bait DNAs
are highly enriched in sequences that are capable of
binding nuclear proteins and nuclear membrane receptors
effectively. An aliquot is cloned at the BamHI site of a
25 vector and 30-40 independent clones are sequenced by
15 priming at a distance of about 50 bp from the inserts.
This yields a first crop of sequences among which known
cis-elements are present, such as SP1 and AP2 sites, N
30 and E boxes, and the like.

20 The remaining sequences in the initial set are
35 analyzed for palindromes. Selected motifs are then
synthesized chemically, tethered to beads and incubated
with nuclear proteins, chromatin or nuclear membrane
fragments. The bound proteins are then isolated
40 25 magnetically and submitted to microsequencing. The
N-terminal sequences are compared to the databank set of
all known open reading frames to find whether the
corresponding genes have previously been sequenced and
45 what, if anything, is known about their function. If the
30 N-terminal sequences are novel, they can be cloned and
sequenced by established procedures.

5 To enhance the isolation of novel cis-elements,
DNA is incubated with nuclear proteins in the presence of
synthetic double stranded DNA bearing the recognition
10 sequence motifs for the most prevalent and ubiquitous
5 transcription factors.

15 The end result of this process extended to
about 10^3 DNA sequences isolated from a variety of tissues
is the isolation and identification of a set of proteins
capable of specific binding to a large set of cis-acting
10 nucleic acid elements. Depending on the tissue, its
20 developmental stage or its pathological status,
non-equivalent sets should be obtained, suggesting ways
to specifically affect transcription for agriculture or
25 biomedical applications.

15

EXAMPLE II

Preparation of a Promoter-Library

30 This example shows a procedure for preparing a
library enriched for promoter sequences.

35 1. Poly-A+ mRNA is isolated from a tissue of
20 interest.

40 2. A first strand is synthesized by reverse
transcriptase primed by random hexamers and in the
presence of Br-dUTP (or digoxigenin-dUTP). The use of
random hexamers increases the probability for complete
25 first strand synthesis extending to the mRNA cap.

45 3. The first strand of single stranded DNA is
annealed to genomic DNA (cut with EcoRI, Hind III) under
50 high stringency conditions.

5
10
15
20
25
30
35
40
45
50
55

4. The 3'-ends of hybrids are extended with Taq DNA polymerase in the presence of biotin-dUTP. In this step, the BrdU-labeled cDNA complementary to the transcribed sequences are extended into biotin-labeled DNA complementary to upstream (promoter) sequences.

5. The sample is digested with a restriction enzyme, such as Sau3A (creates BamHI/BglII-compatible 5'-GATC overhangs). Alternatively, other enzymes (6-cutters) could be used to make longer fragments.

6. The DNA sample is incubated consecutively with [1] anti-mouse IgG beads containing antiBrdU antibodies to purify BrdU-containing DNA (mRNA coding sequences) and [2] streptavidin beads to purify biotin-containing DNA (promoter sequences). Only DNA fragments containing both BrdU and biotin will bind to both beads. This eliminates unextended first-strand cDNA and DNA resulting from non-specific extension during step 4.

The quality of the preparation can be determined by testing for the presence of promoter sequences of known constitutively expressed genes (actin, cyclin, Ku), using primers based on GenBank sequence data.

The promoter library can be used, for example, in the following applications:

A. Use BrdU+/biotin+ fragments as templates for the preparation of random-primed 15- to 20-mer libraries.

5 B. Clone BrdU+/biotin+ fragments into
BamHI-site of plasmid vector for sequencing of individual
products.

10 C. Ligate "adapters" to Sau3A1-ends for
5 single-primer PCR amplification of products.

15 D. Use clones to generate "promoter chips."

20 Throughout this application various publications
have been referenced within parentheses. The disclosures
of these publications in their entireties are hereby
10 incorporated by reference in this application in order to
more fully describe the state of the art to which this
invention pertains.

25 Although the invention has been described with
reference to the disclosed embodiments, those skilled in
30 the art will readily appreciate that the specific
experiments detailed are only illustrative of the
invention. It should be understood that various
modifications can be made without departing from the
35 spirit of the invention. Accordingly, the invention is
20 limited only by the following claims.

Claims

5

10

15

20

25

30

35

40

45

50

55

What is claimed is:

1. A method of identifying a nucleic acid containing a cis acting nucleic acid element, comprising:

(a) contacting a diverse population of nucleic acid binding factors with a diverse population of isolated nucleic acid molecules under conditions that allow said nucleic acid binding factors to selectively bind said isolated nucleic acid molecules; and

(b) identifying one or more isolated nucleic acid molecules that bind to one or more nucleic acid binding factors, said isolated nucleic acid molecules that bind to said nucleic acid binding factors being characterized as nucleic acids containing cis acting nucleic acid elements.

2. The method of claim 1, wherein said diverse population of isolated nucleic acid molecules comprises two or more different nucleic acid molecules.

3. The method of claim 1, wherein said diverse population of isolated nucleic acid molecules comprises greater than about 10^5 different nucleic acid molecules.

4. The method of claim 1, wherein said diverse population of isolated nucleic acid molecules comprises nucleic acids attached to a solid support.

5. The method of claim 1, wherein said diverse population of nucleic acid binding factors comprises two or more different nucleic acid binding factors.

5
10
15
20
25
30
35
40
45
50
55

6. The method of claim 1, wherein said diverse population of nucleic acid binding factors comprises greater than about 10^3 different nucleic acid binding factors.

7. The method of claim 1, wherein said diverse population of nucleic acid binding factors comprises nucleic acid binding factors bound to nucleic acids selected from the group consisting of chromatin, a chromosome, a chromosome arm, a transcriptional domain, a gene family and a gene.

8. A method of isolating a nucleic acid binding factor, comprising:

(a) contacting a diverse population of nucleic acid binding factors with a diverse population of isolated nucleic acid molecules under conditions that allow said nucleic acid binding factors to selectively bind said isolated nucleic acid molecules; and

(b) isolating one or more of said nucleic acid binding factors that selectively bind to one or more of said isolated nucleic acid molecules.

9. The method of claim 8, wherein said diverse population of isolated nucleic acid molecules comprises two or more different nucleic acid molecules.

10. The method of claim 8, wherein said diverse population of isolated nucleic acid molecules comprises greater than about 10^5 different nucleic acid molecules.

11. The method of claim 8, wherein said diverse population of isolated nucleic acid molecules comprises nucleic acids attached to a solid support.

5
12. The method of claim 8, wherein said
diverse population of nucleic acid binding factors
comprises two or more different nucleic acid binding
10 factors.

5
13. The method of claim 8, wherein said
diverse population of nucleic acid binding factors
comprises greater than about 10^3 different nucleic acid
15 binding factors.

20
14. The method of claim 8, wherein said
diverse population of nucleic acid binding factors
comprises nucleic acid binding factors bound to nucleic
acids selected from the group consisting of chromatin, a
25 chromosome, a chromosome arm, a transcriptional domain, a
gene family and a gene.

15
15. A method of identifying a cis acting
nucleic acid element analog, comprising:

30
(a) contacting a diverse population of nucleic
acid binding factors with a diverse population of
compounds under conditions that allow said compounds to
35 selectively bind said nucleic acid binding factors;

(b) contacting one or more of said nucleic acid
binding factors selectively bound to one or more of said
bound compounds with one or more isolated nucleic acid
40 molecules under conditions whereby one or more of said
isolated nucleic acid molecules selectively displaces one
25 or more of said selectively bound compounds from one or
more of said bound nucleic acid binding factors; and

45
(c) identifying one or more of said displaced
compounds, said compounds being characterized as cis
30 acting nucleic acid element analogs.

5
10
15
20
25
30
35
40
45
50
55

16. The method of claim 15, further comprising identifying one or more of said isolated nucleic acid molecules that displaces one or more of said selectively bound compounds, said isolated nucleic acid molecule being characterized as a nucleic acid containing a cis acting nucleic acid element.

17. The method of claim 15, wherein said diverse population of nucleic acid binding factors comprises two or more different nucleic acid binding factors.

18. The method of claim 15, wherein said diverse population of nucleic acid binding factors comprises greater than about 10^3 different nucleic acid binding factors.

19. The method of claim 15, wherein said diverse population of nucleic acid binding factors comprises nucleic acid binding factors bound to nucleic acids selected from the group consisting of chromatin, a chromosome, a chromosome arm, a transcriptional domain, a gene family and a gene.

20. The method of claim 15, wherein said diverse population of compounds comprises greater than about 10^5 different compounds.

5
21. A method of identifying a nucleic acid binding factor analog, comprising:

10 (a) contacting a diverse population of compounds with a diverse population of isolated nucleic acid molecules under conditions that allow said compounds to selectively bind said isolated nucleic acid molecules;

15 (b) contacting one or more of said isolated nucleic acid molecules selectively bound to one or more of said compounds with one or more nucleic acid binding factors under conditions whereby one or more of said nucleic acid binding factors selectively displaces one or more of said selectively bound compounds from one or more of said bound nucleic acids; and

20 (c) identifying one or more of said displaced compounds, said compounds being characterized as nucleic acid binding factor analogs.

25
22. The method of claim 21, further comprising identifying one or more of said nucleic acid binding factors that selectively displaces one or more of said selectively bound compounds from one or more of said bound nucleic acids.

30
23. The method of claim 21, wherein said diverse population of isolated nucleic acid molecules comprises two or more different nucleic acid molecules.

35
40
24. The method of claim 21, wherein said diverse population of isolated nucleic acid molecules comprises greater than about 10^5 different nucleic acid molecules.

45
50
25. The method of claim 21, wherein said diverse population of isolated nucleic acid molecules comprises nucleic acids attached to a solid support.

5
26. The method of claim 21, wherein said
diverse population of compounds comprises greater than
about 10^5 different compounds.
10

27. A method of identifying a compound that
5 selectively binds a cis acting nucleic acid element,
comprising:
15

(a) contacting a plurality of isolated nucleic
acid molecules with a diverse population of compounds
under conditions that allow said compounds to selectively
10 bind said isolated nucleic acid molecules, each isolated
nucleic acid molecule comprising one or more cis acting
nucleic acid elements; and
20

(b) identifying one or more compounds that
selectively bind one or more isolated nucleic acid
25 molecules comprising a cis acting nucleic acid element.
15

28. The method of claim 27, wherein said
diverse population of compounds comprises greater than
about 10^5 different compounds.
30

29. The method of claim 27, wherein said
35 plurality of isolated nucleic acid molecules comprises
between about 2-5 different isolated nucleic acid
molecules, preferably between about 6-10 different
isolated nucleic acid molecules, more preferably between
40 about 11-20 different isolated nucleic acid molecules,
25 most preferably greater than about 20 different isolated
nucleic acid molecules.

30. The method of claim 27, wherein said
plurality of isolated nucleic acid molecules comprises
nucleic acids attached to a solid support.
45
50
55

5
31. A method of identifying a compound that
selectively displaces binding between a nucleic acid
binding factor and a cis acting nucleic acid element or a
10 nucleic acid binding factor, comprising:

5 (a) contacting a diverse population of isolated
nucleic acid molecules selectively bound to nucleic acid
binding factors with a diverse population of compounds
15 under conditions that allow said compounds to selectively
displace one or more of said selectively bound nucleic
10 acid binding factors; and

20 (b) identifying one or more compounds that
selectively displace one or more of said bound nucleic
acid binding factors.

25 32. The method of claim 31, wherein said one
15 or more compounds that displace one or more of said bound
nucleic acid binding factors is a cis acting nucleic acid
element analog.

30 33. The method of claim 31, wherein said one
or more compounds that displace one or more of said bound
20 nucleic acid binding factors is a nucleic acid binding
factor analog.

35 34. The method of claim 31, wherein said
diverse population of compounds comprises greater than
40 about 10^5 different compounds.

25 35. The method of claim 31, wherein said
diverse population of isolated nucleic acid molecules
45 comprises two or more different nucleic acid molecules.

5
36. The method of claim 31, wherein said
diverse population of isolated nucleic acid molecules
comprises greater than about 10^5 different nucleic acid
10 molecules.

5
37. The method of claim 31, wherein said
plurality of isolated nucleic acid molecules comprises
15 nucleic acids attached to a solid support.

38. A plurality of isolated nucleic acid
molecules, each isolated nucleic acid molecule comprising
20 one or more cis acting nucleic acid elements.

39. The plurality of claim 38, comprising
between about 2-5 different isolated nucleic acid
25 molecules, preferably between about 6-10 different
isolated nucleic acid molecules, more preferably between
15 about 11-20 different isolated nucleic acid molecules,
30 most preferably greater than about 20 different isolated
nucleic acid molecules.

40. The plurality of claim 38, comprising
35 isolated nucleic acid molecules attached to a solid
20 support.

41. A plurality of isolated nucleic acid
40 molecules bound to nucleic acid binding factors, each
isolated nucleic acid molecule comprising one or more cis
acting nucleic acid elements.

45
25 42. The plurality of claim 41, comprising
between about 2-5 different isolated nucleic acid
molecules, preferably between about 6-10 different
50 isolated nucleic acid molecules, more preferably between

5 about 11-20 different isolated nucleic acid molecules,
most preferably greater than about 20 different isolated
10 nucleic acid molecules.

43. The plurality of claim 41, comprising
5 isolated nucleic acid molecules attached to a solid
support.

44. A plurality of isolated cis acting nucleic
acid element analogs.

45. The plurality of claim 44, comprising
10 between about 2-5 different isolated cis acting nucleic
acid element analogs, preferably between about 6-10
different isolated cis acting nucleic acid element
25 analogs, more preferably between about 11-20 different
isolated cis acting nucleic acid element analogs, most
15 preferably greater than about 20 different isolated cis
acting nucleic acid element analogs.

46. A plurality of isolated cis acting nucleic
acid element analogs bound to nucleic acid binding
35 factors.

47. The plurality of claim 46, comprising
20 between about 2-5 different isolated cis acting nucleic
acid element analogs, preferably between about 6-10
different isolated cis acting nucleic acid element
40 analogs, more preferably between about 11-20 different
isolated cis acting nucleic acid element analogs, most
25 preferably greater than about 20 different isolated cis
acting nucleic acid element analogs.

5 48. A plurality of isolated nucleic acid
binding factors, said plurality comprising at least about
10 15 different isolated nucleic acid binding factors.

15 49. The plurality of claim 48, comprising
5 between about 16-25 different isolated nucleic acid
binding factors, preferably between about 26-50 different
isolated nucleic acid binding factors, more preferably
greater than about 51 different isolated nucleic acid
binding factors.

20 50. The plurality of claim 48, comprising
10 isolated nucleic acid binding factors attached to a solid
support.

25 51. A method of determining a binding state of
a nucleic acid, comprising:

15 (a) contacting a nucleic acid with a plurality of
isolated cis acting nucleic acid elements under
30 conditions that allow nucleic acid binding factors bound
to said nucleic acid to bind said isolated cis acting
nucleic acid elements; and

35 20 (b) identifying said cis acting nucleic acid
elements that bind to said nucleic acid binding factors,
said cis acting nucleic acid elements that bind to said
nucleic acid binding factors characterizing the binding
40 state of said nucleic acid.

25 52. The method of claim 51, wherein said
binding state is characteristic of a pathological
45 condition selected from the group consisting of cancer,
degenerative diseases, genetic disorders, immune
disorders, bacterial infectious diseases and viral
30 infectious diseases.

5
10
15
53. The method of claim 51, wherein said plurality of isolated cis acting nucleic acid elements comprises between about 2-5 different isolated nucleic acid molecules, preferably between about 6-10 different isolated nucleic acid molecules, more preferably between about 11-20 different isolated nucleic acid molecules, most preferably greater than about 20 different isolated nucleic acid molecules.

20
54. The method of claim 51, wherein said plurality of isolated cis acting nucleic acid elements comprises isolated cis acting nucleic acid elements attached to a solid support.

25
30
55. A method of treating a pathological condition in an individual, comprising administering to said individual an effective amount of one or more therapeutic agents that selectively alter the ability of one or more cis acting nucleic acid elements to regulate a genetic activity of one or more nucleic acids involved in said pathological condition.

35
56. The method of claim 55, wherein said therapeutic agent is a cis acting nucleic acid element.

40
57. The method of claim 55, wherein said therapeutic agent is a cis acting nucleic acid element analog.

45
58. The method of claim 55, wherein said therapeutic agent is a nucleic acid binding factor.

50
59. The method of claim 55, wherein said therapeutic agent is a nucleic acid binding factor analog.

5
10
60. The method of claim 55, wherein said therapeutic agent selectively increases a genetic activity of said one or more nucleic acids.

15
5
61. The method of claim 55, wherein said therapeutic agent selectively decreases a genetic activity of said one or more nucleic acids.

20
10
25
62. The method of claim 55, wherein said genetic activity is selected from the group consisting of nucleic acid replication, repair, packaging, modification, restriction, degradation, transcription, structural integrity, translation, splicing, editing, intracellular transport, localization and reverse transcription.

30
15
63. The method of claim 55, wherein said pathological condition is mediated by the dysregulation of one or more nucleic acids involved in said pathological condition.

35
64. The method of claim 55, wherein said pathological condition is mediated by a pathogen.

40
20
45
50
55
65. The method of claim 55, wherein said pathological condition is selected from the group consisting of cancer, degenerative diseases, genetic disorders, immune disorders, bacterial infectious diseases and viral infectious diseases.

5
10
15
20
25
30
35
40
45
50
55

66. A method of treating a pathological condition in an individual, comprising contacting a cell of said individual with an effective amount of a targeting construct comprising a cis acting nucleic acid element and targeting sequences, said targeting sequences corresponding to a nucleic acid involved in said pathological condition, said contacting being of sufficient duration so as to allow said targeting construct to be taken up by said cell and said cis acting nucleic acid element to be inserted by homologous recombination into said nucleic acid involved in said pathological condition, said inserted cis acting nucleic acid element having the effect of altering a genetic activity of said nucleic acid in said cell.

15
20
25
30
35
40
45
50
55

67. The method of claim 66, wherein said targeting construct contacts a cell in an individual.

30
35
40
45
50
55

68. The method of claim 66, wherein said targeting construct contacts a cell ex vivo and said cell is returned to said individual.

20
25
30
35
40
45
50
55

69. The method of claim 66, wherein said genetic activity is selected from the group consisting of nucleic acid replication, repair, packaging, modification, restriction, degradation, transcription, structural integrity, translation, splicing, editing, intracellular transport, localization and reverse transcription.

45
50
55

70. The method of claim 69, wherein said pathological condition is selected from the group consisting of cancer, degenerative diseases, genetic disorders, immune disorders, bacterial infectious diseases and viral infectious diseases.

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C12N 15/12	A1	(11) International Publication Number: WO 99/10535 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/17283 (22) International Filing Date: 21 August 1998 (21.08.98) (30) Priority Data: 60/056,861 22 August 1997 (22.08.97) US (71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Meng [CN/US]; Apartment 7C, 564 Prospect Street, New Haven, CT 06511 (US). BASKARAN, Namadev [IN/US]; 750 Whitney Avenue, New Haven, CT 06511 (US). WEISSMAN, Sherman, M. [US/US]; 459 Saint Ronan Street, New Haven, CT 06511 (US). (74) Agent: ADLER, Reid, G.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).		(81) Designated States: AU, CA, IL, JP, US; European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN STEM CELLS**(57) Abstract**

The present invention includes a method to identify stem cell genes that are differentially expressed in stem cells at various stages of differentiation when compared to undifferentiated stem cells by preparing a gene expression profile of a stem cell population and comparing the profile to a profile prepared from stem cells at different stages of differentiation, thereby identifying cDNA species, and therefore genes, which are expressed. The present invention also includes methods to identify a therapeutic agent that modulates the expression of at least one stem cell gene associated with the differentiation, proliferation and/or survival of stem cells.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIO SEARCH REPORT

International application No.
PCT/US98/17283

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C12N 15/12

US CL : 435/6; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Medline, WPIDS

search terms: hematopoietic stem cell, differential display

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TAGOH et al. Molecular Cloning and Characterization of a Novel Stromal Cell-Derived cDNA Encoding a Protein That Facilitates Gene Activation of Recombination Activating Gene (RAG)-1 in Human Lymphoid Progenitors. Biochem. Biophys Res. Commun. 1996, Vol. 221, pages 744-749, especially page 744.	1, 2
X	MOREB et al. Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors. Leukemia. July 1997, Vol. 11, Number 7, pages 998-1004, especially page 998.	1, 2



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 NOVEMBER 1998

Date of mailing of the international search report

24 DEC 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN S. BRUSCA

Telephone No. (703) 308-0196

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 3
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

No sequence listing or computer readable form of sequence listing has been supplied, and claim 3 is drawn to specific sequences that therefore cannot be searched.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.